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CHAPTER 1
Diagnosis of Parkinson's disease.

Definition
Parkinson's disease (PD) is an idiopathic, relentless progressive
neurologic disorder and is the most common form of parkinsonism.
Parkinson's disease is considered to be a distinct clinical and
neuropathologic entity, characterized clinically by bradykinesia, resting
tremor, cogwheel rigidity, gait difficulty and postural reflex impairment.
In addition to these cardinal signs there are many motor and non-motor
manifestations of Parkinson's disease, including cognitive, sensory and
autonomie disturbances. Pathologically PD is characterized by the loss of
pigmented neurons, most prominently in the substantia nigra, with
associated very specific eosinophilic cytoplasmic inclusions (Lewy bodies).'
Lewy bodies represent the typical histologie hallmark of PD. Although
pigmented neurons in the substantia nigra degenerate more than the
non-pigmented neurons, the other brain stem catecholaminergic neurons
seem to degenerate regardless of the degree of melanin pigmentation.'
By defining PD in this way all parkinsonism of known etiology is
excluded, as are all disorders with multiple system involvement or
significant lesions of the striatum, such as progressive supranuclear palsy,
olivopontocerebellar atrophy, Shy-Drager syndrome or striatonigral
degeneration. The term 'parkinsonism' refers to any clinical syndrome in
which signs typical of Parkinson's disease are prominent, regardless of the
cause of the condition or its underlying pathologic substrate.
These clinical and pathological criteria, however, are too restrictive and
simple, and they do not take into account the heterogenous clinical and
pathologic presentations of Parkinson's disease and the overlap with
other Parkinsonian disorders, each with presumably distinct etiology. In
the absence of a specific biological marker for PD, the differentiation of
PD from other Parkinsonian disorders rests on clinico-pathologic criteria
that have yet to be rigorously tested and validated/
Diagnosis of Parkinson's disease. A changing nosological
concept.
The English physician and geologist James Parkinson provided the first
clear description of the disorder that now bears his name in a brief
monograph: an Essay on the Shaking Palsy, published in 1817." His
description was based on the observation of only six patients. Three of
these patients were seen by Parkinson 'at a distance', underlining that in
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clinical neurology - as it has developed later on - it is to some extent still
possible to come to a 'diagnose à vue'. After this first description of PD,
paralysis agitans has been defined entirely in clinical terms as a distinctive
syndrome of motor dysfunction. This concept of a particular motor
syndrome has remained firmly entrenched in medical literature,
reinforced in our time by the discovery that the motor syndrome reflects
striatal dopamine deficiency and by the dramatic success of levodopa
therapy.
The nosological concept however of PD as a specific morbid entity has
been undermined by the plethora of parkinsonisms and the paucity of
clinicopathologic correlations.* Is there a true PD plus many other
parkinsonisms? Is the term idiopathic parkinsonism preferable, because it
avoids a firm implication of nosological specificity.'' The profusion of
Parkinson syndromes has given rise to confusion and controversy.
Advances in the identification of distinct parkinsonian syndromes, like
Lewy-body disease, postencephalitic parkinsonism and striatonigral
degeneration, were - to a large measure - due to clinicians working
closely with their colleagues in neuropathology or to clinician-pathologists
such as Raymond Adams and Ludo van den Bogaerdt. The Lewy body in
the substantia nigra came to be recognized as the pathologic hallmark of
Parkinson's disease, the neurofibrillary tangle in the substantia nigra as
typical of postencephalitic parkinsonism, the cytoplasmic argyrophilic
inclusion body as highly specific for multiple system atrophy^, as are the
globose neurofibrillary tangle in progressive supranuclear palsy, the
corticobasal inclusion in corticodentatonigral degeneration and the
argyrophilic grains in argyrophilic grain diseased" Striatonigral
degeneration could be separated from idiopathic parkinsonism on
morphological grounds, even though clinicians could not - at that time -
differentiate the two conditions. Striatonigral pathology seems the most
likely pathology in all non-demented patients with a pure bradykinetic-
rigid disorder and little or no response to a sustained trial of levodopa
given in a large dose. The Parkinsonian disorders were diagnosed on
pathologic criteria by the neuronal morphology present in the substantia
nigra pars compacta, specifically the kind of degenerative inclusion body,
and by the distribution pattern of nerve cell loss elsewhere in the nervous
system.
Increasing knowledge of the Lewy body in the past decade has further
changed our nosological concept. A differential distribution of Lewy body
pathology in the subgroups of the substantia nigra - the ventrolateral part
of the substantia nigra that projects chiefly to the putamen is more
affected than the dorsal part- and the pattern of distribution of Lewy
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bodies throughout the central and peripheral nervous system has led to a
high degree of specificity in the pathology of PD.® In normal aging the
ventral tier of the substantia nigra is not preferentially affected, and this
is associated with a most prominent depletion of dopamine in the
caudate nucleus. PD as a nosological entity has become synonymous with
Lewy body disease, so much so that the finding of incidental Lewy body
disease - in individuals who were asymptomatic in life - is believed to
represent preclinical PD. The concept of idiopathic Lewy body disease
arises from the notion that PD is a part of the spectrum of a wider
degenerative process. It seems surprising but most persons harbouring
Lewy bodies in the substantia nigra do not have - clinical features of -
Parkinson's disease. The reason for this is that Lewy bodies at this site
are found in the general population with a prevalence level of 1% in
persons in their 50s, possibly to as high as 10% in persons in their 80s."
The demonstration of - a variable degree of - Lewy bodies in specific
areas of the cerebral cortex in all patients with idiopathic Parkinson's
disease (i.e. Lewy body disease features in the brainstem) has further
broadened the nosological concept of clinical and pathological PD/ It is
now clear that there is a clinicopathologic spectrum extending from
dementia, with absence or only few clinical Parkinson symptoms and
severe cortical Lewy body involvement with coexisting brainstem Lewy
body pathology, to a clinical syndrome of motor symptoms typical for
idiopathic PD without cognitive decline and morphologically a brainstem
Lewy body pathology with only scanty presence of Lewy bodies in the
cerebral cortex.'' Dementia associated with cortical Lewy bodies however
is rare in the absence of Alzheimer Type Pathology and in these cases
the cortical Lewy bodies are generally believed to be exceptionally
numerous.
It is not precisely known how important Lewy bodies are for Parkinson's
disease. How specific are these inclusions for this particular disease and
what metabolic derangements lead to their formation?'" Lewy bodies
seem to signify neuronal degeneration; and nerve cell loss in PD occurs
with them being found in some of these degenerating nerve cells.
Recently Kremer and Bots" challenged the hypothesis that Lewy bodies
are a sign of significant cell death.
Being aware of these pitfalls in the clinical and pathological diagnosis of
PD, makes an unhesitatingly labelled diagnosis of Parkinson's disease a
nearly impossible task for the neurologist. Chaos seems complete for
neurologists of a former generation if we nowadays are able to recognize
Lewy body disease in the absence of parkinsonism. Alzheimer Type
Pathology in the basal ganglia and substantia nigra without Lewy body
pathology, can be present in non-demented patients with a typical clinical
pattern of idiopathic PD including positive response on levodopa.'^ On
the other hand it has been demonstrated that clinically atypical cases of
PD nevertheless have typical Lewy body pathology.''" Clinical criteria
alone, as Hughes et aP have recently shown, do only imperfectly
differentiate Lewy body parkinsonism from other degenerative disorders
capable of causing parkinsonism. About 20% of patients thought to have
PD during life are found at postmortem examination to have alternative
diseases/ Keeping in mind the frequent occurrence of dementia in PD,
the loose connection of cognitive decline with the degree of coexisting
cortical Lewy body pathology, cell loss in the nucleus basalis of Meynert
with Lewy bodies*" and Alzheimer Type Pathology in the cerebral cortex,
and the finding that one third of patients with Alzheimer's disease have
Lewy bodies at autopsy', makes a statement possible that there is a "pale
body" of evidence to suggest that Parkinson's disease is a mysterious
disorder.
That the neurochemical lesion in (pre)clinical PD can now be visualized
using positron emission tomography (PET) scan technology'*'^, brings us
back to the possibility of a 'diagnose à vue' in clinical neurology. A spot-
PET-diagnosis irrespective of the actual presence of clinical phenomena
like parkinsonism, dementia, focal dystonias and 'simple tremors'."'
Diagnostic criteria for idiopathic Parkinson's disease
The pathological entity of idiopathic PD with Lewy body formation is the
most common cause for the clinical syndrome of parkinsonism. The
symptom complex may also be caused by a vast number of different
pathologic disorders that interfere with the function of the nigrostriatal
dopaminergic system. The major categories of Parkinsonian syndromes
are listed in table I.
Table 1. Classification of parkinsonism
1. Primary parkinsonism
2. Secondary parkinsonism
3. Heredodegenerative parkinsonism
4. Multiple system degenerations
(parkinsonism plus)
Parkinson's disease
Juvenile parkinsonism •
Infectious: postencephalitic, slow virus
Drugs: dopamine receptor blocking drugs
(antipsychotic, antiemetic drugs),
reserpine, tetrabenazine, alpha-
methyldopa, lithium, flunarizine,
cinnarizine
Toxins: MPTP, Co, Mn, Hg, CS2,
methanol, ethanol
Vascular: multi-infarct
Trauma: pugilistic encephalopathy
Other: parathyroid abnormalities,
hypothyroidism, hepatocerebral degenera-
tion, brain tumour, normal pressure
hydrocephalus, syringomesencephalia
Huntington's disease
Wilson's disease
Hallervorden-Spatz disease
Olivopontocerebellar and spinocerebellar
degenerations
Familial basal ganglia calcification
Familial parkinsonism with peripheral
neuropathy
Neuroacanthocytosis
Progressive supranuclear palsy
Shy-Drager syndrome
Striatonigral degeneration
Parkinsonism-Dementia-ALS complex
Cortical-basal ganglionic degeneration
Autosomal dominant Lewy body disease
Alzheimer's disease
The percentage of etiologic categories of parkinsonism has been listed in
table II.
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Table II. Etiologic categories of parkinsonism* (Joseph Jankovic)
Parkinson's disease
Parkinsonism plus
PSP
SDS
OPCA
CBGD
SND
PD/AD
PD/ALS
Secondary parkinsonism
Heredodegenerative parkinsonism
Unknown
Number of
patients
1595
250
154
35
23
18
9
8
3
168
12
27
Percentage
77.7
12.2
7.5
1.7
1.1
0.9
0.4
0.4
0.1
8.2
0.6
1.3
• Baylor College of Medicine, Parkinson's Disease Center and Movement
Disorders Clinic (N = 2052)
CBGD = Corticobasal ganglionic degeneration; OPCA = olivopontocerebellar
atrophy; PD/AD = parkinsonism with severe dementia; PD/ALS = Parkinson's
disease with motor neuron disease; PSP = progressive supranuclear palsy; SDS =
Shy-Drager syndrome; SND = striatonigral degeneration
ldiopathic Parkinson's disease can be characterized clinically by unilateral
onset of symptoms, the initial presentation of at least two of the cardinal
symptoms of tremor, rigidity, bradykinesia and postural imbalance, a
slowly progressive course over more than a few years before marked
degrees of disability are reached, a good to excellent response to oral
levodopa or subcutaneous apomorphine challenges"'*, the absence of
significant changes on computed tomography (CT) scanning other than
mild diffuse cortical atrophies", normal postsynaptic D2 receptor density
in the basal ganglia on [1231] IBZM SPECT-scanning^ and 60-80 percent
reduction in the density of striatal dopamine terminals with [18F]
fluorodopa and [HC]-nomifensine PET scans.""'
About 90% of patients with idiopathic PD improve on levodopa, but the
response to levodopa is not helpful in accurately predicting the
pathologic diagnosis.
Table III lists the criteria used by the United Kingdom Parkinson's
Disease Society Brain Bank.'" •, .•: , .;••,.
Table III. Clinical diagnostic criteria for idiopathic Parkinson's disease
Presence of at least two of:
bradykinesia
muscular rigidity
4-6 Hz resting tremor
postural instability (primary visual, vestibular, cerebellar or proprioceptive
dysfunction excluded)
Unilateral onset
Persistent asymmetry
Absence of clinical exclusion criteria
Excellent response to levodopa (70-100%); sustained for 5 or more years
Clinical course of 10 years or more
Two major clinical subtypes of PD may be identified: one characterized
by tremor and the other dominated by 'postural instability and gait
difficulty'. The tremor subtype PD is associated with relative preserved
mental status, earlier age at onset and slower progression of the disease.
Whether these subgroups represent distinct disorders, separate from PD,
is uncertain. Rajput et al." found Lewy bodies at autopsy only in 27% of
patients with the 'postural instability - gait difficulty' form of idiopathic
parkinsonism.
Table IV. Accuracy of differential diagnosis of Parkinson's disease
Alternative diagnosis on clinical grounds
4% Progressive supranuclear palsy
6% Olivopontocerebellar atrophy
7% Drug-induced parkinsonism
20% MSA
Alternative diagnosis on pathological grounds
18% Clinical idiopathic Parkinson's disease brains
6% Strictly defined clinical idiopathic Parkinson's disease
(striatonigral degeneration, progressive supranuclear palsy )
50% Pathologically proven striatonigral degeneration diagnosed as
idiopathic Parkinson's disease in vivo
Considerable debate exists regarding the diagnostic accuracy of clinical
PD. Werner Poewe" has summarized some studies that have addressed
the difficulty to make a correct (differential) diagnosis. His findings are
listed in table IV.
It has become a common procedure to establish a set of features in
patients' history, neurological signs and symptoms that are incompatible
with a firm diagnosis of clinical PD. These features are summarized in
table V.
Table V. Exclusion criteria for idiopathic Parkinson's disease
History of definite encephalitis
History of repeated stroke with acute onset and/or stepwise progression of signs
History of dopamine antagonist treatment prior to onset
Sustained remission
Oculogyric crises
Supranuclear gaze palsy (downward or lateral)
Cerebellar signs
Early severe dysautonomia
Early severe dementia
Babinski sign
Negative response to maximum tolerated doses of levodopa and apomorphine
Incompatible findings on CT/MRI
However this list of exclusion criteria may have flaws. Gibb" proposed
that exclusion criteria for the diagnosis of PD must include also more
than one affected relative. It is not uncommon for Parkinsonian patients
to report other family members affected with the disease. In fact the
genetics of PD have been studied extensively in the past, with generally
inconclusive findings. Studies of mitochondrial dysfunction in PD
(reduced mitochondrial complex I in the substantia nigra) have bolstered
a growing body of evidence supporting a genetic component - with
inheritance from the maternal genome." The non-Mendelian inheritance
pattern of mitochondrial DNA would explain low concordance rates for
PD in twins.''' The classic study of Ward et al.' found no significant diffe-
rence in concordance rates between monozygotic and dizygotic twins. The
findings of Brooks et al." - by demonstrating reduced putamen [18F]
dopa uptake by PET in three of six monozygotic and two of three
dizygotic unaffected PD co-twins - suggest however that many of the twin
pairs originally reported to be discordant for PD, may well have been
concordant if preclinical PD could have been detected.^ Golbe'' recently
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reported a large kindred with PD and observed that a single abnormal
genome may be capable of producing clinical and pathologic PD. It has
become attractive and provocative to make a philosophy on PD as an
autosomal dominant disorder. The data already available suggest the
hypothesis that Lewy body Parkinson's disease is part of the clinical range
of expression of an autosomal dominant disorder'' with partial age-related
penetrance, long premorbid and prodromal phases and marked variability
of clinical manifestations extending beyond the motor syndrome of
parkinsonism, upon which our traditional concept of PD is based.
Only recently some risk factors for Parkinson's disease have been
established: rural living, pesticide use, male life style, family of neurologic
disease and history of depression.^
I am grateful to Roger Duvoisin and Werner Poewe for helpful
comments on this chapter.
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CHAPTER 2
The pharmacotherapy of Parkinson's disease.
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Introduction
The primary biochemical deficit in PD is the loss of dopamine in the
basal ganglia, resulting from degeneration of dopamine-producing cells in
the substantia nigra. The cause of the degeneration of dopaminergic
containing cells and appearance of Lewy bodies in the zona compacta of
the substantia nigra in patients with PD remains unknown. As a
consequence of this dopamine loss in the striatum the neurotransmitter
balance (particularly the balance between acetylcholine and dopamine) is
altered and clinical symptoms emerge.
Symptomatic therapy refers to an intervention that ameliorates the
clinical features of illness, but benefits are only temporary as the
neurodegenerative disease progresses. Levodopa is an example of
symptomatic therapy for PD: symptoms are lessened temporarily by
levodopa and exacerbated upon its withdrawal (e.g. wearing-off effects)
Protective therapy represents an intervention that substantially protects
the population of vulnerable neurons and thereby slows the underlying
progression of neurodegeneration. Recent studies in the cause of PD
have suggested that nigral damage manifestating as PD may result from
either extrinsic causes such as exogenous neurotoxins similar to MPTP
acting directly or indirectly via oxygen free radicals, or intrinsic causes
such as free radicals and other toxins produced during the MAO-B-
catalysed breakdown of dopamine (i.e. the oxidative stress hypothesis).'
The antioxidative strategy of MAO-B-inhibition^ has led to a growing
enthusiasm in the clinician's vocabulary for terms like neuroprotection.
Recently evidence has accumulated that the neuroprotective effect of
MAO-B-inhibitors is probably not a result of MAO-B-inhibition.
Selegiline does achieve neuronal rescue via activation of a 'neurotrophic-
like' mechanism."* Neuronal rescue may account for the reported slowing
of progression of PD, reported in various clinical trials"""' with the so-
called MAO-B-inhibitor selegiline.
Symptomatic therapy
To provide symptomatic relief anticholinergics and amantadine generally
are prescribed. Anticholinergics seem particularly useful in (younger)
patients who are bothered by tremor, but these compounds can produce
neurobehavioural side effects, such as forgetfulness. This adverse effect
on memory has thrown discredit on anticholinergics. Amantadine has also
modest anti-parkinson properties, is generally well tolerated, and thus
offers a useful alternative, particularly in the elderly patients.
Amantadine is recently thought to have an indirect anticholinergic effect
by blocking glutamate (NMDA) receptors.*
In fact, Olney et al7 have proposed that NMDA-antagonists should be
considered as potential antiparkinsonian drugs. These compounds reduce
the overactivity in the glutamatergic cortico-striatal and subthalamic
nucleus - globus pallidus tracts. It is hypothesized that the rate of
progression of dopaminergic nigrostriatal degeneration coincides with a
progressing functional increase of these glutamatergic pathways. These
excitatory aminoacids like NMDA play a pivotal role in the 'motor loop'
( = the nigrostriatal dopamine system and its striatonigral GABA-ergic
counterpart) and in the 'complex loop' (= the tight connections of the
basal ganglia - i.e. the ventral striatum - with the ventrolateral/
ventromedial portions of the thalamus, the limbic system and the
prefrontal- and the frontal-association cortex"). The 'complex loop'
interfaces anatomically with the 'motor loop' so that behaviourial
interconnections are possible. The Dutch scientist Nauta' must be given
full credit for his exciting neurobehavioural studies. Papez circuit,
connecting hippocampus and anterior thalamus, has shown to be of a
more complex nature. Brain areas like part of the frontal isocortex, the
entorhinal cortex and septal regions are innervated by dopaminergic
fibres, which mainly originate in the ventral tegmental area.
Glutamatergic fibres connect cortical and limbic brain areas; and the
perforant pathway - connecting the entorhinal cortex with the
hippocampal sub-areas - uses glutamate as transmitter." Attention has
therefore been focused in recent years on these regions of the brains,
their dopaminergic-glutamatergic inhibitory and excitatory influences, and
their involvement in psychiatric and neurobehaviourial signs and
symptoms in PD and its modulation with dopamimetics, anticholinergics
and glutamatergic therapies.
Whether selegiline - as a MAO-B-inhibitor - may also act on NMDA
receptor modulation is uncertain at the moment.^ But the increased
dopamine activity induced by selegiline - by virtue of its inhibition of
dopamine enzymatic breakdown and its property to reduce dopamine re-
uptake - certainly gives selegiline a place in the symptomatic therapeutic
modalities in PD. Especially in the early stages of the disease, while
symptoms are still mild and in order to delay the introduction of
levodopa.
tfierapy
Dopamine-precursor therapy remains the single most effective therapy
for the symptomatic treatment of PD. Its remarkable success has made it
the gold standard against which all new forms of therapy need to be
compared. It is the centrepiece of drugtherapy in PD. Levodopa therapy
is far from perfect, however. As the number of levodopa-therapy years
mount and as the underlying disease process inevitably advances, a
greater share of the motor and non-motor response to levodopa becomes
contaminated by response fluctuations, dyskinesias, other abnormal
sensitizations to dopamine stimulation, and eventually poor
responsiveness, 'tolerance', or unresponsiveness to levodopa. '"•"•'*
Ultimately response fluctuations become increasingly difficult to live with
and complex to manage, partly because of their unpredictable timing of
manifestation, and the response to levodopa itself becomes part of the
disability.
Whether these levodopa-complications are more related to - the duration
of - levodopa therapy or - to duration of - the disease has been debated
ever since these adverse effects and response-losing first became
recognized. The shortening of levodopa's half life in the striatum is
probably the most important etiologic factor, as a consequence of loss of
the striatum's ability to store and buffer the shifts in exogenous
levodopa/dopamine concentrations, and the development of
supersensitive post-synaptic dopaminereceptors." Strategies designed to
prolong and smooth out the therapeutic plasma levels of levodopa thus
have been developed. Intermittent oral levodopa administration leads to
intermittent absorption with resulting fluctuations in plasma levels, which
in turn leads to repeated cycles of relative dopaminergic activation and
withdrawal. Other peripheral pharmacokinetic properties of levodopa
contribute to fluctuations in plasma: short distribution and elimination
half-lives (30 minutes and 214 hours respectively), depending mainly on
enzymatic decarboxylation and O-methylation." Although gastric
emptying and the short plasma half-life of levodopa contribute greatly to
response fluctuations, they do not explain individual differences in these
fluctuations over the course of the illness. These phenomena only can be
understood by central pharmacokinetic and pharmacodynamic factors in
the handling of levodopa and dopamine.
The pathophysiology of the increasing motor complications and declining
antiparkinsonian efficacy of chronically administered levodopa in patients
with severe PD remains to be fully elucidated. Current observations allow
the hypothesis of Thomas Chase" to be advanced that wearing-off
phenomena occur largely as a result of dopamine-terminal degeneration
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due to natural disease progression. On-off fluctuations and peak-dose
dyskinesias, on the other hand, appear to reflect secondary, only partially
reversible, alterations at the postsynaptic level - probably as a
consequence of intermittent stimulation of normally tonically activated
dopamine receptors. Dl and D2 dopamine receptor-mediated
mechanisms are affected differently by the basic disease process and by
dopaminomimetic therapy.
Slow release preparations of oral levodopa, such as 'Sinemet CR' and
'Madopar HBS', offer the possibility of 'smoothing out' clinical fluctuati-
ons by slowly releasing the levodopa from a special matrix. These
compounds are useful in the treatment, and possibly prevention, of motor
fluctuations, particularly the wearing-off phenomenon. The percentage of
patients, however, with increased 'on' time without dyskinesias after these
slow released preparations generally is small. Moreover a disadvantage of
these compounds is the more slowly functioning in the morning.
Raymund Roos et al.'* recently suggested that if the initial levodopa
concentrations are not in the critical range to be effective for the patient,
the advice should be to take the controlled-release levodopa preparation
in a fasted condition. There are no significant differences in the clinical
efficacy and adverse events of these two slow-release preparations,
although there are definite differences in some of their pharmacokinetic
parameters."' Contrary to the encouraging short-term effects, long-term
slow release levodopa treatment does not seem to produce long lasting
benefit in most patients with response fluctuations.
Other methods currently investigated in an attempt to provide more
continuous dopaminergic stimulation include duodenal infusions of
levodopa." A continuous delivery of dopamine to the striatum can also
be accomplished, experimentally, by encapsulated slow-release polymer
systems which are subcutaneously implanted.
Catechol-O-methyltransferase (COMT) inhibitors added to levodopa and
decarboxylase inhibitors have theoretical advantages in the management
of motor symptoms of PD and possibly also in the avoidance of response
fluctuations, as has been suggested by Kaakola et al.'"* and Roberts et
al.'""
Finally one must take into account that some motor and non-motor
response-fluctuations, postural disturbances and neurobehavioural
symptoms are not only refractory to levodopa therapy in its own right,
but may substantially limit the tolerance to standard antiparkinson
medications.
These agents have the advantage of directly stimulating dopamine
receptors, thereby bypassing the requirement for native decarboxylase.
One can achieve a certain degree of selective stimulation of the various
subtypes of dopamine receptors, and this may confer some advantage,
although this is as yet not entirely clear for their clinically relevant
efficacy.
Bromocriptine is the prototype dopamine agonist, has a longer duration
of action than levodopa (4 to 6 hours) and is highly selective for D2
receptors, with a minor inhibitory activity on Dl receptors.''^ Pergolide is
more potent than bromocriptine, has a longer duration of action than
bromocriptine (approximately 8-10 hours) and stimulates both Dl and
D2 receptors."" The potential role for Dl receptor stimulation in PD is
not clear at the time - on the one hand it might increase the incidence of
dyskinesias, on the other hand Dl stimulation might be necessary to
modulate the D2 stimulation.
The efficacy of these two dopamine-agonists may be similar, although
recent reports suggest a significant more sustained motor response with
pergolide, and patients obtain new benefit when they are switched from
bromocriptine to pergolide, whereas no benefit has been shown by
substituting bromocriptine for pergolide.""
Dopamine-agonists stimulate presynaptic dopamine-receptors and
consequently decrease dopamine turnover. This might be relevant to a
reduction of oxidative stress and may provide neuroprotective properties
of pergolide, as suggested by Felten et al."'" Another important - possibly
protective - mechanism of pergolide has been an increase of superoxide
dismutase (SOD) in the striatum." The deactivation of superoxide
radicals by SOD, thus induced by pergolide, favour the use of pergolide
early in the course of PD.
Dopamine-agonists have been used as monotherapy and seem effective in
reducing the eventual development of fluctuations and dyskinesias.-'' The
antiparkinson potency of dopamine-agonists is, however, inadequate for
any length of time. For this reason levodopa and dopamine-agonist
combination therapy has proved useful for keeping the dose of levodopa
low and significantly lowering the incidence of motor fluctuations and
dyskinesias. Weiner et al." recently could not observe that early
combination therapy (bromocriptine and levodopa) delayed or prevented
the onset of late treatment complications, and levodopa monotherapy
resulted in greater improvement in PD disability. An interim report of a
Japanese study of Kondo et al.*, however, established a superior efficacy
of pergolid over combination therapy as initial treatment. Pezzoli et al."
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recently compared the efficacy of pergolide and bromocriptine and
concluded that pergolide as adjunctive therapy to levodopa is more
effective than bromocriptine.
Regardless of the neuroprotective properties of pergolide, the conclusion
might be drawn that dopamine-agonist therapy is highly recommended as
a late adjunct to levodopa in patients already experiencing response
fluctuations and dyskinesias.
Cabergoline, a potent D2 agonist, with a half life of about 65 hours (!), is
currently being tested in clinical trials. The increase of dyskinesias,
induced by cabergoline, seems to be a serious adverse event.^"'"
Since 1987 Apomorphine, a potent Dl and D2 dopamine-agonist, has
been introduced in the treatment of motor fluctuations of PD.**
Apomorphine is - to some extent - water soluble, quickly equilibrates
between peripheral and central compartments, and is therefore highly
suitable for intravenous, subcutaneous, sublingual and intranasal
administration.^'^ Transdermal delivery devices for Apomorphine are
being studied at the moment. Also rectal administration of Apomorphine
is effective, not for a rapid-acting remedy for sudden or predictable
'freezing' episodes, but to acquire a long-duration response.
The use of Apomorphine has only been made possible by concomitant
use, in the first weeks of treatment, of an anti-emetic such as
domperidone. In this way it has come to a rediscovery of this first
dopaminergic drug. Apomorphine is widely used as subcutaneous
injection to quickly reverse the 'off period, or as subcutaneous infusion
using a portable pump to achieve a continuous effect. The magnitude and
other features of motor and nonmotor responses to apomorphine are
similar to those produced by levodopa, only incidentally symptoms can be
improved that are unresponsive to levodopa or that are to be rewarded
as side-effects of levodopa therapy/' The item of tolerance to the
pharmacologie effects of Apomorphine is still a matter of debate." Long-
term follow-up of continuous subcutaneous Apomorphine pump
treatment in patients with Parkinson's disease, by Werner Poewe et al.,
could not substantiate a tolerance to Apomorphine.^
Long-term subcutaneous apomorphine infusions definitely are efficacious,
but generally many practical, compliance, biochemical and new bizarre
peak-dose dyskinesia problems have to be dealt with. In this regard
subcutaneous application of Apomorphine injections are the most simple
and practical procedure to use this oldest dopamine-agonist.^
Possibly neuroprotective therapies in Parkinson's
disease.
Early detection of preclinical Parkinson's disease (greatly exceeding
clinically overt PD in prevalence*"'™*); postmortem studies of 'incidental'
Lewy body disease (10 percent of the population dying in the ninth
decade of life have Lewy bodies associated with a degree of ventral tier
nigral cell loss'); the visualization on the fluorodopa scan of neuronal loss
occurring at the same rate before clinical expression of PD"'"'; exposure
to the neurotoxic designer drug MPTP (with subtle cognitive
impairments found in MPTP-exposed mild cases comparable to those
found in early P D ^ « « * « ) ; the pivotal role of the MAO-B-inhibitor
selegiline in the prevention of neurotoxicity of MPTP* and in the inhibi-
tion of oxidative metabolism of dopamine; and the role of endogenous
and exogenous hydroxyl free radicals (= oxidative stress ) for the
dysfunction of mitochondrial complex I and lipid peroxidation.'"'" All
these phenomena are exciting and recent findings that are very relevant
to the pathogenesis of PD and to the development of the concept of
neuroprotective therapies.
These topics have been discussed in detail in literature.''*'''"'' Bloem et al.""
hypothesized on the versatile contributions of the MPTP model to the
treatment of idiopathic PD. That the result of DATATOP''"'' was that
selegiline is capable of delaying the onset of disability associated with
early, otherwise untreated PD, has divided neurology in
'DATASTOPPERS' and 'DATATOBBERS'.
The consequence of DATATOP seems to be that, although the action of
selegiline that accounts for its symptomatic or protective beneficial effects
remains unclear, selegiline is worldwide adviced to be used in the early
phases of PD and that dopamimetics or dopamineprecursors be added
when symptoms are sufficiently severe to require it. DATATOP study
learned that the time from diagnosis to need for levodopa is
approximately 1 to 2 years.
Examination of the shorter-acting MAO-B-inhibitor Lazabemide, which is
not metabolized to active (i.e. amphetamine) compounds may help clarify
the undoubtedly beneficial action of selegiline.'"'
For etiopathogenesis of PD five mechanisms seem relevant:
1. MPTP induces parkinsonism by virtue of its MAO-B-transformation to
MPP+ +, which is a specific inhibitor of NADH-COQ-Reductase.*''™
2. Increased iron (III) and total iron content in postmortem substantia
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nigra, with a catalytic activity on the production of hydroxyl free
radicals.'""" Iron's accumulation in substantia nigra is attributed to its
delocalization from ferritin. 6-hydroxydopamine (6-OHDA) and Nitric
Oxide (NO) are thought to owe their toxicity to release of iron bound
to ferritin. NO, which can be synthesized by exitotoxic glutamatergic
neurons, thus is an endogenous compound to release iron, directly
interfering with complex I mitochondrial activity, and interacting with
iron in the process of oxidative stress.
3. A specific nigral glutathione deficiency in PD."
4. The finding of an ongoing oxidative stress in nigral cells of PD patients
by dopamine metabolites (free radicals and nitric oxide), which lead to
dysfunction of mitochondrial complex I.***
5. Disturbances in function of key enzymes that are important in
endogenous metabolism, but also important for the safe metabolism of
a variety of xenobiotics (S-oxidation and S-methylation reactions).
Some individuals may have a genetic susceptibility to develop PD
based on the reduced ability to metabolize toxins from the
environment or to inactivate toxic radical species formed within the
body."*
Neurons in the substantia nigra pars compacta are particularly vulnerable
to oxidant stress because":
a. The metabolism of dopamine generates peroxides which in the
presence of iron leads to the formation of the highly reactive hydroxyl
free radical.
b. Neuromelanin within nigral neurons binds metals such as iron and
aluminium, and promotes the site-specific formation of free radicals.
The increased iron, decreased glutathione and increased lipid peroxidati-
on in the substantia nigra pars compacta support this hypothesis. The
high neuromelanin content of the substantia nigra is believed to result
from the auto-oxidation of dopamine.
Selegiline has many pharmacological properties'*, some of which are
summarized here:
1. a. Dopamine re-uptake inhibition
b. Facilitation of the release of dopamine
c. Enhancement of dopamine synthesis.
2. Pharmacologie activity of the L-methamphetamine metabolite of
selegiline, possibly relevant to the awakening, 'activating' or anti-
depressant properties of selegiline.
3. Increase of Phenylethylamine, which modulates or amplifies DA
response.
J0
4. MAO-B-inhibition . . . . • . - . ^
a. relevant to symptomatic benefits of selegiline as a consequence of a
dopamimetic effect.
b. Interference with the oxidative metabolism of dopamine, thereby
diminishing free radical formation.
5. Neuroprotection by increased formation of SOD, catalase and
suppression of formation of oxidized glutathione.
6. Acting as anti-oxidant itself, (personal communication Prof. A. Bast)
7. Neuronal Rescue*
a. (re)activation of astrocytes and trophic factors (NGF): rescue
injured neurons.
b. enhancement of substantia nigra neuronal activity.
c. prevention of age related changes in the neurons of the substantia
nigra.
Some of these unsuspected actions of selegiline can fully account for the
reported slowing of the progression of PD in the DATATOP-study.
Critical for this role of selegiline is a dosage insufficient to inhibit MAO-
B. William Tattons' hypothesis is that low dose selegiline rescues, and
high dose selegiline kills; the so called 'kissing and killing' model of
selegiline.'
Seventy-one percent of dopamine in the human brain is metabolized
outside the neurone by MAO-B, and four percent by MAO-B inside the
neurone.'"' Twelve percent is oxidized inside the neurone by MAO-A.
This raises the question whether MAO-A inhibition should also be
studied in the symptomatic and protective treatment of PD.
Aims of the thesis.
1. Summarize the pitfalls in clinical diagnosis of Idiopathic Parkinson's
disease.
2. Review current developments in the etiopathogenesis and
pharmacotherapy in Parkinson's disease.
3. Investigate the clinical benefits of two sustained-release levodopa
compounds ('Madopar HBS' and 'Sinemet CR') and one dopamine-
agonist ('Parlodel SRO') in pharmacotherapy of Parkinson's disease.
4. Describe some of the results of research with the dopamine-agonist
Apomorphine.
5. Report the increase of Parkinsonian disability provoked by treatment
with the serotonin re-uptake inhibitor Fluoxetine.
6. Report the efficacy of Clozapine - an atypical neuroleptic agent - in
the alleviation of rest-tremor in Parkinson's disease.
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CHAPTER 3
Neuroprotection by selegiline?'
'Neuroprotectie door selegiline? ENH Jansen, Neef C. Pharm Weekbl 1992;127-
(21):571-575.
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Parkinson's disease is characterized as a dopamine-deficiency syndrome
in the nigrostriatal system. As a consequence of neuronal degeneration in
the zona compacta of the substantia nigra, a loss of dopamimetic
innervation of the corpus striatum (nucleus caudatus and putamen) arises
reducing the concentration of dopamine in this corpus striatum. There is
a correlation between this cellular loss in the substantia nigra, the loss of
dopamine in the corpus striatum and the clinical phenomena of
Parkinson's disease (especially the rigidity and the hypokinesia).'^
Clinically Parkinson-phenomena don't come through until a cellular
loss of 60% in the substantia nigra, and a loss of dopamine in the corpus
striatum of 80%. Also the Tyrosinehydroxylase quantity in the substantia
nigra has then diminished with 80% with regard to the normal situation.
It is certain that a long period of constant neuronal degeneration
precedes the clinical manifest phase of Parkinson's disease. It is supposed
that there is a phase of many years of the 'presymptomatic parkinsonism'.
It is the hypothesis that this neuronal degeneration results from an
accelerated ageing process or from the fact that after an endogenous or
exogenous damage of the cells of the substantia nigra a 'normal' ageing
process brings about the degeneration/"
Meanwhile this presymptomatic and clinical dopamine deficiency in the
striatum can be visualized and quantified^ with the positron-emission
tomography (PET-scan). There has also been shown a positive correlation
between the severity of the dopamine-deficiency (registered with PET-
scan) and the degree of clinical phenomena of Parkinson's disease.''
If there are medicines that can slow down the speed of progression of
Parkinson's disease, then early diagnosis - and if possible also recognition
of the presymptomatic stage - is essential in Parkinson's disease. In future
this may happen with the help of 'biomarkers'.
Present-day levodopa substitution in Parkinson's disease aims at
improving symptoms and during the last 25 years has led to dramatic
improvement of the quality of life and increase of life-expectancy for
about 70% of the idiopathical Parkinson patients." Only a part of the
problems with long-term levodopatherapy is a result of levodopa itself, so
that nowadays postponement of levodopatherapy is no longer considered
absolute.'*
Free radicals and neurotoxines * ^ !
The cause of cell death in the substantia nigra with Parkinson's disease is
unknown, but it is taken for granted that demolition of neurones may
arise by exogenous toxins and by oxygenradicals which are generated by
the oxidative deamination by monoamine-oxidase-B (MAO-B) of
dopamine.'' First the putative role of free radicals is considered; then the
influence of neurotoxines is under discussion. Finally light is thrown upon
the importance of MAO-B-inhibitors in the treatment of Parkinson's
disease, especially with the help of the Datatop study.
Free radical hypothesis
The idea that the enzymatic oxidation of dopamine can be 'self-killing'
for the nigrostriatal neurones by the formation of hydrogen peroxide and
other oxygenradicals has become clearer of late years. Above all the
oxidative damage of proteins, lipids and DNA has been subject of study.
Free radicals and toxins damage the neurones of the substantia nigra by
lipid peroxidation. In Parkinson's disease^hjs^ process is increased. Then
it is a question of increased oxidative stress.'""" In consequence of this the
normal detoxification of dopamine and its metabolites is disturbed. We
are concerned here with the following factors:
* the dopamine-'turnover' is enhanced through which more oxygen
radicals are generated. Dopamine is deaminated oxidatively by the
enzyme MAO-B:
^ -.#2^2*^2 +semic/iinones
* The formed peroxides and superoxides can be converted via the
Haber-Weiss-reaction and the Fenton-reaction into the most toxic
radical, the free hydroxyl radical (*OH). Iron plays the part of
catalyst in these reactions'^:
increase of the MAO-B-activity with age and in Parkinson's disease'";
* the iron-quantity in the substantia nigra is highly increased in
Parkinson's disease'";
* the body possesses some intracellular enzymatic defense mechanisms
against free radicals, namely: glutathionperoxidase, catalase and
superoxide-dismutase. Also vitamin E (tocopherol) is intracellular
active as 'scavenger' catching away the free radicals. The 'scavenger'-
enzymes catalase and glutathione-peroxidase are highly reduced in
the substantia nigra of Parkinson-patients"^.
As a consequence of above-mentioned factors the process of lipid
peroxidation is intensified and the ultimate cell destruction in the
substantia nigra is promoted.
Finally it is worth-while mentioning that an increased free radical
forming can selectively bring about a damage of the complex-1 (NADH-
ubichinon-Reductase) in the mitochondria, which decreases the synthesis
of ATP-ase and the energy formation in the cell. A decreased
concentration of complex-1 was recently shown in cells of the substantia
nigra in patients with Parkinson's disease.""'*
Neurotoxine hypothesis
Of late years interest has grown in the idea that one or more
neurotoxines play a prominent part in neuronal degeneration, as in
Parkinson's disease. This new interest has especially come into being after
Langston's discovery in 1982 that methylfenyltetrahydropyridine (MPTP;
or in fact the metabolite MPP*) is very selectively neurotoxic for the cells
of the substantia nigra (and the locus coeruleus).' It may induce a
syndrome that is practically indistinguishable (not neuropathologically
either) from idiopathic parkinsonism.' The mechanism with which this
toxicity of the substantia nigra is realised so selectively, has meanwhile
been partially cleared. A noticeable experience of this research into the
pathophysiology of this 'toxic-parkinsonism' was that with it a decreased
complex-1-quantity was found in the mitochondria of the lesioned
substantia nigra, likewise also with idiopathic parkinsonism.
The discovery of a toxic compound which can cause parkinsonism has
led to a scientific concept that the origin of Parkinson's disease is possibly
(also) caused by toxic compounds as they occur in our internal or
external environment. Honestly speaking must be assumed that a 'MPTP-
like' compound has not yet been discovered in our environment up to the
present. Neuroepidemiologic research will play an important part in the
future as far as this is concerned. This has been assumed by Barbeau in
the province of Quebec (Canada) in 1986 in his attempt to correlate the
prevalence of Parkinson's disease to the use of the insecticide
paraquat."-"
Crucial in neurotoxicity of MPTP is the biotransformation to MPP*, by
the MAO-B enzyme. MAO-B inhibitors are able to prevent this
biotransformation completely and with it also the damage of
dopaminergic cells in the substantia nigra. This is also the reason that
MAO-B inhibitors have become so interesting in the causal treatment of
Parkinson's disease. MAO-B inhibitors could be able to delay the process
of nigrostriatal degeneration.
MAO-B, free radical-hypothesis and neurotoxine-hypothesis
Already sooner mention was made of the importance of the MAO-B in
the pathogenesis of Parkinson's disease. In short it concerns the following
factors:
* MAO-B is responsible for the oxidative deamination of dopamine, a
process which generates free radicals;
* MAO-B realizes the biotransformation of the protoxine MPTP to the
toxic MPP*;
* the MAO-B activity increases with normal ageing and also with an
affection in which normal or accelerated ageing processes play a part,
as with Parkinson's disease'";
* the MAO-B activity is increased in thrombocytes and in the substantia
nigra of Parkinson-patients'".
MAO-B-suppression (selegiline)
The activity of selective suppression of the MAO-B enzyme can be
explained two-fold:
* selegiline suppresses MAO-B, it decreases the re-uptake of dopamine.
It also has an effect on the presynaptic dopamine receptors, through
which the dopamine-release is facilitated. The dopamine concentration
is enhanced by this. So selegiline has a dopaminergic effect. A
beneficial effect on the symptoms of Parkinson's disease may be the
result hereof. With selegiline it is possible to postpone the
levodopatherapy as a result of this symptomatic effect or, with on-going
levodopatherapy, to decrease the dosage;
* selegiline prevents the formation of toxins (for example from
protoxines like MPTP) and toxic free radicals. This antineurotoxic
effect may offer protection to dopamine neurons against further
demolition by the process of lipid peroxidation.
In such a case you can speak of neuroprotection.
The first beneficial effect of selegiline in Parkinson's disease was
mentioned in the retrospective research of Birkmayer et al.*' They
reported a longer duration of life with patients who had been treated
with a combination of levodopa and selegiline, than in a group of
patients that had been treated with levodopa only. Elizan et al. found a
synergistic effect of the combination levodopa and selegiline.^ Already
sooner these researchers had reported a weak symptomatic but not
neuroprotective effect of the addition of selegiline to ongoing levodopa
medication. The break-through in the research into the activity of
selegiline came from the Datatop-study on-a-large-scale in the U.S.A."
Datatop stands for 'Deprenyl And Tocopherol Antioxydative Therapy Of
Parkinsonism'.
The Datatop-research questions the fact whether treatment with
selegiline 10 mg a day could be able to postpone the point of time, in
which the Parkinson disability has become so severe that levodopa
therapy is considered necessary. The primary end-point of the study had
been - with so far untreated Parkinson patients - the starting point of
levodopa therapy. This starting-point which had been correlated to the
degree of disability, was clearly defined beforehand. The study also
looked at the effect of tocopherol - 2000 I.E. a day - (vitamin E) - in
combination with selegiline or otherwise, in a double-blind placebo-
controlled research protocol. At present only the interim analysis is
known of the data about selegiline. The complete research data won't be
known until 1992. The research was prematurely broken off by the
research committee of the study in 1989, because the beneficial effects of
selegiline medication appeared to be so significant, that it was ethically
unjustified to continue the study in unaltered form. As with every break-
down of research there was the chance that in interim analysis the extent
of the effect was systematically overrated.
In the study 800 Parkinson patients were involved; 401 patients were
randomized for placebo, 399 patients for selegiline. The measured
therapy compliance was exceptionally high (97-99%).
The measured interval from the beginning of medication for the reach
of the end-point (necessity of levodopa) was 15 months in the placebo
group and 26 months in the selegiline group (statistical significance:
'°
In the placebo group the end-point was reached by 176 patients, and in
the selegiline group by 97 patients. This difference is statistically
significant (p<10®). Administration of selegiline resulted in 50%
reduction of speed of disability progression, and slowed down the
progression of disability itself with almost a year.
With such an obviously measured beneficial effect of selegiline the
interpretation of the acquired results remains a difficult matter. Has a
decreased progression of the disease been shown herewith
(neuroprotection in narrower sense), or has the postponement of the
levodopa therapy partly been realized by a dopaminergic and thus
symptomatic effect of selegiline-medication?
In the Datatop-study a small but significant improvement was reported
in the disability-score (the Unified Parkinson Disability Rating Scale;
UPDRS) in the with selegiline treated group, but only after 1 and 3
months' therapy. This so-called 'wash-in'-effect suggests an initial
symptomatic effect of selegiline. This effect was 1.5 point on the UPDRS-
scale (a total score of 125 points is possible). This small symptomatic
effect of selegiline does not explain that selegiline slows down the
reaching of the end-point. This was also ruled out as a consequence of
measuring the disability-score at a point of time that the biological effect
of selegiline had disappeared after stopping the medication. This 'wash-
out' period lasted for a month. In the Datatop-study there seemed to be
no 'wash-out'-effect at this moment of time: the disability score which was
measured with the UPDRS had not deteriorated. This pleads strongly
against the argument that the activity of selegiline could only be
explained by a symptomatic-dopaminergic effect. At least, if a month is
sufficient for the complete inactivation of biological active selegiline.
That's the reason why in the U.S.A. there is a research going on into
fixing the 'wash-out'-effect 2 months after stopping the selegiline
medication.
This Datatop-study has not given any certainty about the question
whether selegiline protects against degeneration of neurones in the
substantia nigra in Parkinson's disease. But the result of this study so
incontestably brought to light that selegiline can postpone the progression
of disability as a consequence of Parkinson's disease, and that selegiline
can so postpone the levodopa therapy, that this will have extreme
consequences for the medical treatment of this d iseased
The many criticisms and comments on this Datatop-study have recently
been concentrated in a very critical article.** Ample reactions were given,
in such a way that the results of the Datatop-study, after having been
undone from myths and misinterpretations, remained on end.** Only as a
consequence of a small anti-Parkinson and anti-depressive activity of
selegiline the unprecedentedly high significance of the effect of selegiline
on the speed-reduce of progression is unexplainable. Prescribing
selegiline as soon as possible after diagnosing 'Parkinson's Disease' is
therefore recommended/'
As has been reported, the final conclusions of the Datatop-study will
not be published until mid 1992. Only then will definitely be reported
which precisely is the part of selegiline in the medical treatment of
Parkinson's disease. It does not seem unlikely that after this, additional
research - if possible on even great scale as the Datatop-study as well -
will be necessary to make clearer the position of selegiline as
neuroprotective or as dopaminergic medication.
Conclusion
The pharmacotherapy of Parkinson's disease had until recently been
aimed at the treatment of the consequences of neuronal degeneration,
namely levodopa substitution therapy. The results of this levodopa
therapy are impressive and are not equalled by the treatment with
dopamine-agonists or suchlike medications with a symptomatic
dopaminergic effect.
Recent opinions in the pathophysiology in Parkinson's disease, among
other things the hypothetical role of MAO-B in the production of free
oxygen radicals and other toxins, have led to an important role of MAO-
B inhibitors in the treatment of this disease. The present-day data of
experimental neuro-pharmacological and clinical neurological research
have led to the certainty that with selegiline the symptomatic therapy
with levodopa substitution can be postponed, and that selegiline in all
probability delays the progression of disability of Parkinson's disease.
In a practical sense this has the following consequences for treatment:
* selegiline medication as initial therapy in Parkinson's disease. With
increasing disability are added to this (in the following order)
dopamine-agonist and levodopa substitution. Levodopa is as most
powerful weapon last placed in position. Selegiline medication being
continued"'";
* in going-on medication of levodopa and/or dopamine-agonist,
selegiline is added on behalf of a levodopa-saving effect and to
decrease the speed of clinical progression of the malady. Then as a rule
it is possible to decrease the dosage of the on-going levodopa therapy,
among other things to ameliorate dyskinesia or other dopaminergic
side-effects**; -
• in obviously progressed cases of Parkinson's disease, when moreover
the motor response to levodopa therapy has been extinguished, there
seems to be little room for medication with selegiline.
Parkinson patients with obvious or reasonably to be expected high degree
of levodopa responsivity can derive much benefit from selegiline,
especially at long-term. If by future research is confirmed that selegiline
has neuroprotective qualities, then further research into presymptomatic
parkinsonism is desirable. Neuroprotection with MAO-B-inhibitors
should in such a case be able to reduce or delay symptomatic levodopa
therapy.
Selegiline is not only an irreversible selective MAO-B-inhibitor, but it is
also a reversible inhibitor of the (re)uptake of dopamimetic and MPTP-
like compounds in the dopaminergic neurones.
Further research will have to make clear how these two functions of
selegiline can be separated and which function is actually the most
important one.
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CHAPTER 4
Open multicenter trial with Madopar HBS in parkin-
sonian patients. Preliminary assessment after short-
term treatment.*
"E.N.H. Jansen, J.D. Meerwaldt, Th. Heersema, J. van Manen, J.D. Speelman.
Eur Neurol 1987;27(suppl. l):88-92.
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After some years the benefit derived from levodopa in the treatment of
Parkinson's disease decreases slowly. After 6 years of levodopa therapy
the initial benefit is maintained in only 30% of patients. Furthermore, in
the course of several years of levodopa therapy they develop an
increasing number of side effects, of which abnormal involuntary
movements, response fluctuations and yo-yoing and painful off-period
cramps or dystonias are the most frequent to be encountered.' In a
recent survey*, 93% of patients after 10 years of levodopa therapy did
exhibit the one or the other of these side effects, or a combination of
them. The most problematic group of patients, however, is the one that
exhibits the so-called 'drug resistant fluctuations'; about 10% of
parkinsonian patients develop these fluctuations after 5 years of levodopa
therapy.
The main reasons for the waning efficacy of levodopa and/or for the
increasing number of side effects are: (1) relentless progression of the
underlying pathology in the nigrostriatal pathway, including continued
reduction of the dopamine storage capacity in the basal ganglia; (2)
pharmacodynamic problems resulting in changes in receptor affinity"*; (3)
pharmacokinetic problems leading to a short-duration response'; and (4)
formation of 3-O-methyldopa in- and outside of the brain, which reduces
evidently the bioavailability of levodopa^.
Furthermore, the fluctuations in response may reflect the short half-life
of the drug which, in addition, is erratically absorbed and distributed in
patients who critically depend for good motor function upon adequate
delivery of levodopa to their striatum.'
As the number of dyskinesias and response fluctuations are largely
explained by or related to the variations in plasma levels of L-dopa, a
controlled-release form of L-dopa reducing the peak levels of L-dopa in
plasma and producing a steadier plasma concentration of levodopa has
been developed based on the principle of the hydrodynamically balanced
system of Madopar; the so-called Madopar HBS7
We report here our preliminary results of short-term treatment with
this Madopar HBS. :
Patients and Methods
Twenty-three patients with idiopathic Parkinson's disease, all with some
5/
kind of response fluctuations, were selected for this study (table I).
Table I. Patient data (23 patients with Parkinson's disease)
Men, n
Women, n
Age, years
Duration of illness, years
Under levodopa therapy, years
Disability (Hoehn and Yahr scale)
III, n
IV, n
Dosage standard Madopar, mg
Dosage bromocriptine
(in 12 patients only), mg
14
9
52-72 (61.2)
5-26 (13.4)
4-14 (9.6)
12
11
406-1,750(723)
(36)
Informed consent was obtained after approval of the protocol by the
hospital elhical committee. The parkinsonian signs and symptoms have
been evaluated according to the Hoehn and Yahr scale*, and the North-
western University Disability Scale (NUDS)'' and the Webster rating
scale'". The fluctuations in motor performance were scored using a list of
the different types of fluctuations, scored from 0 (absent or disappeared)
to 4 (extremely severe) as well as by a global assessment of these
phenomena. Moreover, the patient or spouse kept a record of the times
when he or she was dyskinetic, hypokinetic, or eukinetic on a card in
which each quarter of an hour is one unit. The different aspects of motor
behaviour have different colours: green = eukinetic, yellow = akinetic
and red = dyskinetic or dystonic (fig. 1). With this self-rating system,
designed by J.D.M., the frequency and duration of fluctuations can be
monitored. This Meerwaldt patient card is filled in on 3 consecutive days.
The total number of fluctuations in these 3 days is added up, and the
mean of each type of fluctuations per day is calculated. Likewise, the
total number of 'units' red, yellow and green per day is calculated, which
yields a measure of the duration of fluctuations per day and their
respective ratios. At the beginning of the study and at the end of the
dose adaptation phase the Hoehn and Yahr scale, the Webster scale, the
NUDS and the Meerwaldt patient card were filled out. At the end of the
dose adaptation phase, the investigator also stated his personal opinion
of the effects of Madopar HBS, as compared with the standard form, on
the evolution of the parkinsonian symptoms, on the fluctuations in
general and on the global tolerance.
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Figure 1. Model of Meerwaldt's patient card, a self-rating system of
motor fluctuations. Green = eukinetic; yellow = akinetic; red
= dyskinetic or dystonic.
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At the same time the overall effect of this new formulation was
evaluated by the investigator and the patient in order to decide whether
treatment with Madopar HBS should be continued or if the previous
treatment should be resumed.
The standard Madopar treatment was switched abruptly to Madopar
HBS treatment in all 23 patients. The initial daily dosage of the Madopar
HBS was increased by 25% as compared to the previous standard
Madopar dosage. This increase in dosage was decided because the
bioavailability of Madopar HBS is less than that of standard Madopar.
The dosage was further increased if parkinsonian symptoms deteriorated
or if the levodopa response was felt to be too unstable or too short. The
frequency of administration of Madopar HBS was reduced only after a
stable dose adaptation phase had been reached (or earlier if necessary).
Madopar HBS was the only drug available to the patients during this
dose-finding period of 3 months.
Results
All 23 patients completed the study as planned in the protocol. There
were no premature terminations of the treatment for reasons unrelated
to the drug. The increase in dosage incurring with the switch from
standard Madopar to Madopar HBS in the total group is summarized in
table 11. At the end of the 3-month dose-finding period the average
overall increase in levodopa dosage amounted to 391 mg or 54%.
Table II. Dosage (mg)
Mean Range
Initial standard Madopar 723 406-1,750
Madopar HBS 1,114 500-2,500
Average increase 391 (54%) 125-875
2,500 mg Madopar HBS = 20 capsules = 2,000 mg
L-dopa daily.
Three patients did not tolerate an increase in dosage of Madopar HBS as
small as 125 mg; while they showed an increase in the duration of the
'on' periods, they suffered from enhanced abnormal involuntary
movements. Another 3 patients had similar problems after an increase of
the dosage of Madopar HBS; they also showed an increase of abnormal
involuntary movements, however, they tolerated an increase in dosage
higher than 125 mg Madopar HBS. Two patients did not tolerate the
abrupt switch from standard Madopar to Madopar HBS, as they
developed severe akinesia and, after further increase in dosage of
Madopar HBS, remained akinetic without any beneficial response from
Madopar HBS administration. These patients had to be considered as
primary treatment failures.
Eight patients reported a marked prolongation of the latency of the
early-morning levodopa response; this could be counteracted partly by an
increase of the first morning dose of levodopa and/or by administration
of the first dose at an earlier time.
Two patients had a recurrence of early-morning dystonia" under
Madopar HBS treatment, which could not be reduced by rescheduling
the timing or by changing the dosage.
At the end of the study, 2 patients who started the study with a clear-
cut end-of-dose deterioration showed a significant improvement of
parkinsonian symptoms and a reduction of the response fluctuations.
They also remained in a eukinetic state for longer periods during the day.
Eight patients had a minimal or questionable improvement at the end of
the dose adaptation phase. Continuation of treatment with Madopar
HBS was considered as justified in these two groups of patients.
Thirteen patients returned to their previous standard Madopar
treatment, because parkinsonian signs or symptoms deteriorated and/or
because dyskinetic phenomena increased in intensity or duration under
Madopar HBS despite increased dosage of Madopar HBS and/or
rescheduling of the timing of levodopa administration.
The findings recorded with the Meerwaldt patient card are shown in
table III. In the total group there was a small increase in yellow units, at
the expense of a decrease of the mean value of green units. The total
number of red units did not change for the group as a whole. The
number of daily fluctuations was somewhat reduced, i.e. the mean value
of daily fluctuations dropped from 9.4 to 8.4.
The Hoehn and Yahr scale, the Webster rating scale and the NUDS
did not reveal any changes in the group as a whole after the switch from
standard Madopar to Madopar HBS. The decision whether or not to
continue treatment with Madopar HBS was not based on the results
obtained with these rating scales. The total number of yellow units of
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Table III. Meerwaldt's patient card
Yellow, units
Green, units
Red, units
Daily fluctuations,
1 unit - 1 quarter
n
of an hour.
Standard
Madopar
16.3
33.8
9.9
9.4
Madopar
HBS
19.6
30.3
103
8.4
the Meerwaldt patient card, however, did correlate positively with the
decision to stop the treatment with Madopar HBS after the dose-finding
period.
Discussion
Twenty-three patients entered a study in which standard Madopar was
abruptly replaced by the new galenic form Madopar HBS in an attempt
to reduce fluctuations in performance and 'on-off phenomena. After a
dose-finding period of 3 months and an overall increase of levodopa
dosage by 54%, only 2 patients - with clear-cut end-of-dose deterioration
- showed a significant improvement in response fluctuations. Thirteen
patients showed no improvement or considered the change from standard
Madopar to Madopar HBS as a step backwards, either with regard to
response fluctuations or with regard to parkinsonian signs and symptoms.
Patients with random oscillations or yo-yoing, or patients with profound
diurnal swings in motor performance showed no benefit from Madopar
HBS treatment.
The positive effects of Madopar HBS, i.e. the reduction of fluctuations
in performance, were often obtained at the expense of the major negative
effect of Madopar HBS, i.e. unacceptable delay to 'turn-on' in the
morning. In patients with a 'low therapeutic index' Madopar HBS was
not beneficial. Early-morning dystonia recurred in 2 patients under
Madopar HBS regimen. The poor result of Madopar HBS in this study
may be related to the bioavailability profile of the HBS compound. The
relative bioavailability of Madopar HBS compared to standard Madopar
is about 60%. Thus, the poor results obtained with Madopar HBS in
some patients in this study may have been a matter of dosage. The
increase in dosage of levodopa by 54%, after switch to Madopar HBS,
evidently was not always sufficient to compensate for this marked
reduction of bioavailability. Moreover, for a sustained response a higher
plasma concentration of levodopa might be necessary than for a
threshold response obtained with intravenous levodopa.'*" Possibly, with
Madopar HBS the increase in dosage might be much more substantial
than the one necessary to compensate just for the reduced bioavailability.
Another reason for the relatively poor results may have been that
parkinsonian patients cannot be switched to a therapeutic regimen with
Madopar HBS only, i.e. they need additional standard Madopar in order
to prevent the major disadvantage of this Madopar HBS: the increased
latency after the first morning dose.
In a study design in which only parkinsonian patients with end-of-dose
deterioration would be selected, the beneficial effects of Madopar HBS
might be much more pronounced.
The patient card of Meerwaldt is an easy and reliable way of measuring
frequency and intensity of fluctuations in motor performance.
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CHAPTER 5
Madopar HBS in Parkinson patients with nocturnal
akinesia/
^Ernst N.H. Jansen and Jan D. Meerwaldt. Clinical Neurology and Neurosurgery,
1988, vol. 90-1:35-39
F* t
Introduction
Nightly disabilities are quite common in Parkinson's disease (PD),
although in the literature these nocturnal problems are only infrequently
mentioned.'""' Sleep disturbances, nocturnal immobility and frequently
interrupted sleep, may be a consequence of the disease itself. Another
factor, however, may also play a role: after treatment with levodopa for
more than five years many patients develop a variety of dose-limiting and
disabling side effects, including dyskinesias, and a complex syndrome of
deterioration of drug efficacy indicating the emerging of tolerance to
levodopa", of which response fluctuations are the most troublesome.
These response fluctuations may be dose-related, for instance the genuine
'wearing off phenomenon, or occur at random and in an unpredictable
manner, the 'on-off phenomenon'.' The 'off-phase does not only show
the akinetic problems of Parkinson's disease itself, but may also take the
form of invalidating painful 'off-period' pain, spasms and dystonia.'"
The most unpleasant and incapacitating painful 'off-period' phenomena
do not only occur during the day but are also frequently registered during
the night and/or the early morning. Thus Parkinson patients are not only
awakened because of immobility but also because of these painful
dystonic phenomena.
The pathophysiological mechanisms underlying this tolerance to
levodopa are poorly understood*, but the pharmacokinetic influences
seem predominant as causative factors: the short half-life of levodopa,
the fluctuations of the levodopa level in the plasma and the striking
influence of the duration of levodopa therapy on the development of
these response fluctuations.'^ Long-term therapy with levodopa + Dopa
Decarboxylase Inhibitor (DDI) seems to provoke these phenomena
earlier and more frequently than therapy with only levodopa does."
We have carried out an open trial of a sustained-release preparation of
levodopa Madopar-Hydrodynamically Balanced System (HBS)'"" in 15
Parkinson outpatients with severe response fluctuations due to chronic
levodopa treatment and suffering from severe nightly disabilities.
Patients and Methods
Fifteen outpatients with idiopathic Parkinson's disease (7 women and 8
men) were studied. Their mean age was 60 years (range 33 to 78) and the
mean duration of the parkinsonian symptoms was 12 years (range 5 to
67
17). The mean duration of the levodopa therapy was nine years (range 2
to 13). All patients were on levodopa, nine patients had levodopa plus a
peripheral decarboxylase inhibitor (in 6 patients benserazide, in 3 patients
carbidopa), and six patients had plain levodopa. The mean dosage of
levodopa (calculated without the DDI part) was 785 mg (range 531 to
1000). The number of daily doses of levodopa ranged from 4 to 16. No
patient took levodopa ante noctem, but four patients took their first
levodopa at 5 a.m., either to decrease early morning dystonia or to
alleviate early morning akinesia. Seven patients had additional dopamine
receptor agonist therapy (bromocriptine), mean dosage 35 mg (range 20
to 37.5). According to the Hoehn and Yahr scale*, four patients had a
motor disability stage III, 10 patients stage IV and one patient stage V.
All patients had response fluctuations during the day: 13 patients had a
wearing-off phenomenon, the other response fluctuations are summarized
in Table 1. . . . . . . . . - ,
Table 1. Diurnal fluctuations
Symptoms Number of patients
peak-dose dyskinesias 10
off-period dystonias 5
end-of-dose effects 13
random on-off fluctuations 2
early morning dystonia 1
15 patients
Table 2. Night-time disabilities
nocturnal akinesia
nocturnal off-period pain
early morning akinesia
early morning dystonia
nocturnal dyskinesia
15 patients
1 * number of patients prior to Madopar HBS
2* number of patients after Madopar HBS
(Î2
15
1
12
1
0
2
0
8
2
2
All 15 patients included in this study had severe nightly disabilities,
which could be divided into four groups: (1) nocturnal akinesia, and
consequently frequent awakenings, micturition with problems getting to
sleep afterwards; (2) painful off-period cramps (dystonia or spasms); (3)
early morning dystonia and (4) early morning akinesia. The patients
could be categorized in more than one group, see Table 2. Madopar HBS
was administered only once a day: ante noctem, and according to the
intensity of the sleep disturbances the dosage was varied from 125 to 500
mg. The daily amount of levodopa and the number of doses and their
schedule were kept unchanged. After six months the assessment of the
efficacy of the addition of this ante noctem Madopar HBS to the
conventional levodopa regimen was based on the subjective findings of
the patients in the four groups of nightly disabilities and on the global
assessment of their quality of sleep.
Results •.! "
Fourteen patients completed the six-month open study on the addition of
Madopar HBS ante noctem to an otherwise unchanged levodopa
substitution therapy. The dosage of Madopar HBS ranged from 125 to
500 mg; 5 patients were treated with 125 mg, 1 patient with 250 mg, 6
patients with 375 mg and the other 3 patients with 500 mg (mean dosage
308 mg). Table 2 shows the overall results.
While all 15 patients had nocfunjo/ a/arces/a before the institution of
Madopar HBS, 13 patients had a considerable or even dramatic
diminution of the akinesia; in four patients the nocturnal akinesia had
completely disappeared, providing an undisturbed sleep for these
patients. In eight patients the nocturnal akinesia was diminished to such
an extent that they could turn around in bed again, and/or were more
self-supporting in getting out of bed and walking to the toilet. The one
patient with nocturnal off-period pain and cramps in the legs, which
generally awakened her at 3 a.m., had a painfree sleep after 375 mg of
Madopar HBS. Further increase of the dosage to 500 mg Madopar HBS
ante noctem, provoked nocturnal dyskinesia. In an early study''* this
patient had shown a reduction of diurnal off-period cramps after the
administration of Madopar HBS in the daytime, at the cost of an
intolerable increase of peakdose dyskinesias, which were more disabling
than the off-period cramps.
morning a/aVjesza, which was present in 12 patients, was only
slightly alleviated in four, and this did not establish a functional
improvement in their daily-life activities. This slight alleviation was
achieved on a dosage of 125 mg of Madopar HBS ante noctem in three
patients. The other patient in this group was treated with 375 mg.
£ar(y mor/î/ng rfysfoma was present in one patient prior to the madopar
HBS therapy and disappeared after treatment with Madopar HBS. But
early morning dystonia occurred in two other patients. The dosage of
Madopar HBS ante noctem in these two patients was relatively high (500
mg) because of very severe nocturnal akinesia. The efficacy of the
Madopar HBS in these two patients on the nocturnal akinesia was quite
remarkable, and as a consequence the mild early morning dystonia was
taken into the bargain.
Two patients had manifestations of nocfuma/ ofy /^ne^w after treatment
with Madopar HBS. In one patient this could be controlled by a
reduction of the dosage from 500 to 375 mg ante noctem, without
affecting the beneficial effect on nocturnal akinesia. The other patient
suffered severe nocturnal dyskinesias after only 125 mg of Madopar HBS
ante noctem. Although a previously present severe nocturnal akinesia had
disappeared by this small dosage of Madopar HBS, the patient and his
wife could not put up with these dyskinesias and the therapy with
Madopar was stopped. One patient with a regimen of 375 mg Madopar
HBS ante noctem and 600 mg Sinemet and 25 mg Bromocriptine in the
daytime, had a slight increase in dyskinesias and longer on-periods during
the day.
/Irfverse e/fecte of this nocturnal Madopar HBS regimen were rare. No
patients had gastrointestinal side-effects. Psychiatric complications were
not seen, only one patient felt a little drowsy, which could be overcome
by a reduction of the dosage of Madopar HBS from 500 to 375 mg. One
other patient became restless during the day, which subsided
spontaneously.
The global improvement of the sleep quality could be related to the
consumption of sleeping tablets. After treatment with Madopar HBS ante
noctem, sleeping pills were used regularly by only one patient, compared
with eight patients who regularly took sleeping pills before the treatment
with Madopar HBS.
Discussion
Patients with idiopathic Parkinson's disease show significantly reduced
REM sleep and more frequent and prolonged waking through the night."
It has been suggested that this disturbed sleeping pattern is related to a
reduction in brain amines.'®'"
Treatment of Parkinson's disease with levodopa or a dopamine agonist
is said to lead to an improvement of the quality of sleep, in accordance
with the fact that the severity of disease is directly related to the
impairment of sleep."" The sleep disturbances in PD patients consist of a
light-fragmented sleep pattern, with increased muscle activity, which can
be reversed by treatment with pergolide, a strong and selective D,
agonist, in contrast to levodopa which influences the whole population of
D receptors''". Apps et al" found reduced stages III and IV sleep only in
patients in a severe state of disease (Hoehn and Yahr stages IV and V).
Long-term levodopa therapy causes a high frequency of unwanted
effects, of which the wearing-off effects, dyskinesias and dystonias, and
severe fluctuations in therapeutic response are the most frequently
encountered.**^^ In a recent study" 90% of long-term levodopa-treated
PD patients showed these phenomena of the 'long-term levodopa
syndrome'.
At the same time it is common for PD patients to have profound
nocturnal problems due to aAc/nef/c weanVzg-o/f p/zertomerta. In their light-
fragmented sleep they are frequently awake in an akinetic state,
incapable of turning around in bed, or of going to the toilet. Also, many
PD patients are awakened by painful off-period cramps, and dystonias.
For many PD patients the night is a nightmare at the end of which only
few patients have the so-called sleep benefit; they are incapacitated by
early morning dystonia or early morning akinesia. For these reasons,
many PD patients use sleeping pills or take their last levodopa dosage at
2 a.m. to prevent early nocturnal problems, and their first levodopa at 5
a.m. to prevent early morning problems.
In this study a new sustained-release compound - MADOPAR HBS -
was administered only ante noctem in a dosage of 125 to 500 mg. The
very good results, related to frequency of wakening and nocturnal
akinesia, verify the pharmacological sustained-release profile of this
compound. The major disadvantage of Madopar HBS in daily
administration, i.e. unacceptable latency of efficacy'* was not seen with
the nocturnal administration of Madopar HBS and may even be an
advantage in nighttime administration. The same holds true, though less
pronounced, for the increase in dyskinesias. The capacity of Madopar
HBS taken ante noctem to reduce the early morning akinesia or early
morning dystonia is evidently too small; this is in accordance with the
biopharmacological profile of this compound. 375 Milligram of Madopar
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HBS produces an adequate plateau level of plasma levodopa for only
some hours.** The occurrence of early morning dystonia in two patients in
this study is in accordance herewith. The tolerance to Madopar HBS was
excellent. No gastrointestinal adverse effects were registered. This is
possibly related to the fact that these patients already used levodopa +
DDL No untoward effects were encountered by the use of two DDI's in
some patients (carbidopa and benserazide). A sustained-release levodopa
compound such as Madopar HBS seems a safe and effective method of
reducing the invalidating nocturnal problems of patients with Parkinson's
disease on long-term levodopa therapy.
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CHAPTER 6
Clinical efficacy of Sinemet CR 50/200 versus Sinemet
25/100 patients with fluctuating Parkinson's disease.
An open, and a double-blind, double-dummy, multi-
center treatment evaluation.''
'EC Wolters, MWIM Horstink, RAC Roos, T van Laar, ENH Jansen and the
Dutch Sinemet CR Study Group. Clin Neurol Neurosurg 1992;94:205-211

Introduction "
Levodopa, in combination with a peripheral dopadecarboxylase inhibitor,
still constitutes the basis of therapeutic strategies in Parkinson's disease.
Long-term treatment with this drug, however, is limited because of loss of
levodopa responsiveness in most patients. Patients may suffer predictable
wearing-off periods and/or unpredictable on-off periods with random
swings in motor functioning.''^ These motor fluctuations are said to be
associated with the pharmacokinetic and pharmacodynamic properties of
oral levodopa?'' Sustained, continuous intravenous infusions with
levodopa, resulting in stable plasma levodopa levels, proved to be
successful in the treatment of those fluctuations?
Keeping plasma levodopa levels stable in this way is, however, not very
practical during long-term treatment. A practical solution, in the form of
controlled-release preparations with pharmacokinetic properties more or
less similar to those of intravenous infusion, has been sought. A formula
containing a slowly erodible polymer matrix with 50mg carbidopa and
200mg levodopa (Sinemet CR-4 = Sinemet CR), proved to be quite suc-
cessful in this respect." This formula induces a sustained rise in plasma
levodopa level, lasting 2-3 h longer than with Sinemet STD?
Clinical trials with Sinemet CR showed this drug to be as safe and as
well tolerated as conventional formulas.™ Sinemet CR was found to
reduce the incidence and duration of daily off-periods, with fewer doses
per day, but at a higher total daily dosage of levodopa than with Sinemet
STD. Open studies*"" showed significantly improved clinical efficacy of
Sinemet CR as compared with Sinemet STD, but this could not be
unequivocally confirmed in double-blind studies/'-""
In this study we compared the efficacy and tolerability of Sinemet CR
and Sinemet-STD in Parkinson's disease patients with motor fluctuations,
both in an open and a double-blind fashion.
Methods
The study lasted 32 weeks and was divided into 2 phases. The first phase
was an 8-week open-label dose-finding period of 4 weeks Sinemet STD
(weeks 1-4) and 4 weeks Sinemet CR (weeks 5-8), in which end-readings
were compared to the measurements at the start of the study
(baseline-1).
The second phase was a double-blind, double-dummy period of 24
7/
weeks (weeks 9-32), during which period half of the patients received
Sinemet CR plus placebo Sinemet STD, and the other half received
Sinemet STD plus placebo Sinemet CR. Here the end-results were
compared with the assessments at week 8 (baseline-2). The dosage and
dose schedule for this double-blind period were established during the
dose-finding periods, but investigators were allowed to alter both drug
regimens (Sinemet or Sinemet CR and placebo) at the same time.
Patients were randomly selected to receive therapy according to a scheme
which provided equal distribution of patients concurrently receiving a
stable dose of dopamine agonists in both groups. If considered necessary
for the patient's welfare, drugs for other physical conditions were allowed
in a stable dosage.
Physical examination and routine laboratory tests, including a complete
blood cell count and electrocardiograms, were performed at
commencement and at the end of the study. Safety measures included
monthly recordings of adverse clinical experiences. Tolerability of the
drug was recorded. Dosage and dose frequency were established based on
clinical response. Evaluations of the clinical response during this study,
performed at commencement and at weeks 4, 8, 12, 16, 20 and 32,
included: (1) the New York University Parkinson's Disease Scale
(NYUPDS) to determine clinical efficacy in terms of rigidity, tremor,
bradykinesia, gait and postural stability; (2) the North-western University
Disability Scale (NUDS) for the evaluation of daily activities such as
walking, dressing, eating, feeding, hygiene and speech; (3) patients'
diaries for the evaluation of on-off periods and sleep pattern; (4)
patients' overall evaluations of early morning akinesia, dystonia,
dyskinesia, and pain. Evaluations were recorded on a 5-point scale; (5)
physicians' and patients' overall assessment (on a 5-point scale), including
their opinion about the actual medication during the double-blind period
in order to test the 'blindness' of this study.
Fifteen Dutch neurologic departments entered 84 patients with
Parkinson's disease. Hoehn and Yahr stages II-IV, with motor
fluctuations. A total of 15 patients withdrew during the study: 7 patients
during the titration period, 8 during the double-blind period. Five of
these withdrawals were due to adverse effects, of which three were
Sinemet CR-related. Six withdrawals were due to insufficient therapeutic
response, of which four during the Sinemet CR dose-finding period. Four
patients were excluded from analysis a posteriori because of protocol
violation (3), or having been lost to follow-up (1). Clinical characteristics
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of the remaining 69 patients (34 in the Sinemet STD and 35 in the
Sinemet CR group) are given in Table 1. Based on statistical analysis
(Student's t-test and binomial difference test), both groups were
comparable at the start of the study. Of the STD-treated patients, 32 re-
ceived concomitant antiparkinson therapy, such as bromocriptine,
selegiline and amantadine. In the CR-treated patients this accounted for
26 persons. This concomitant therapy remained constant in all patients
during the study. Pharmacologically treated conditions, other than
Parkinson's disease, occurred equally in both groups: depression,
insomnia, anxiety, coronary heart disease, hypertension and chronic
obstructive pulmonary disease.
Paired results were separately studied in both open-label and
double-blind phases:
I. Ope/i-/ai>e/ rturfy: The results of all participating patients (n = 69)
during the open-label titration phase at baseline (week 1), week 4 (end of
titration period STD)
and week 8 (end of titration period CR).
//. DouWe M/u/ .rtittfy.
(1) STD-group: results of the patients treated in the double-blind phase
with Sinemet STD plus placebo Sinemet CR (n = 34), at weeks 8
(baseline-2) and 32.
(2) CR-group: results of the patients treated in the double-blind phase
with Sinemet CR plus placebo Sinemet STD (n = 35) at weeks 8
(baseline-2) and 32.
Student's t-test was used to discriminate between the effects on several
variables. The incidence of clinically adverse experiences in the 2
treatment groups was compared during the double-blind phase by means
of Student's t-test. The level of significance was reached at P ^0.05.
Results
Efficacy (Fig. 1, Table 2)
Mean (SD) total NYUPDS scores as obtained during the open-label
study in all patients at baseline (6.9 ± 2.7) and week 4 (6.4 ± 2.7) and
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Figure 1. Mean of total NYUPDS
(upper) and NUDS (lower) scores with
standard deviations (SD) in: 69
Parkinson patients at baseline-I (BLj),
week 4 (after optimal STD titration)
and week 8 (after optimal CR
titration); 34 patients, treated double-
blind with STD, at baseline-2 (BL,,
week 8) and at week 32 (end of the
s tudy) ; 35 pa t i en t s , t r ea t ed
double-blind with CR, at BLj and week
32. NYUPDS = New York University
Parkinson's Disease Scale; NUDS =
North-western University Disability
Scale. Significance: wk 8 vs. BLj and
wk 32 vs. BL2; 'P < 0.05, " P < 0.01;
wk8 vs. wk4:<*'>P < 0.01.
OPEN-1ABEL DOUBLE-BI.IND
SIT) CR
NYUPDS
NUDS
Sinemel STD
Sinemel CD
Table 1 Survey of clinical characteristics of the evaluated patients at start
of the study
Male/female
Age(years)
Levodopa
dosage (mg day)
No. of doses, day
Parkinsonian disability
NUDS
NYUPDS
Hoehn and Yahr stage
Duration in years of
Parkinson's disease
fluctuations
STD (n = 34)
Mean (SD)
24:10
60.8(9.3)
642(285)
5.5(2.2)
11.0(4.8)
6.9(2.6)
2.9(0.4)
10.6(5.2)
4.2(2.7)
CR (n = 35)
Mean (SD)
19:16
61.6(8.4)
632(295)
5.3(2.7)
10.8(5.7)
6.9(2.8)
2.8(0.8)
10.4(4.6)
3.4(2.8)
P
(STD
vsCR)
NS
NS
NS
NS
NS
NS
NS
NS
NS
STD = Sinemet standard 25/100. CR = Sinemet CR 50/200. SD standard deviation.
NS = not significant. NUDS = North-western University Disability Scale. NYUPDS
= New York University Parkinson's Disease Scale.
week 8 (5.4 ± 2.5) showed that CR-titration induced significant
improvement of the clinical condition at week 8, as compared both with
the situation at baseline and after STD-titration at week 4. There were
no differences in response to STD or CR between the group ultimately
assigned to STD in the double-blind portion and the group assigned to
Sinemet CR. In the double-blind STD-treated patients a statistically
significant increase in total NYUPDS score at week 32 (6.0 ± 2.9) as
compared with week 8 (5.3 ± 2.2) was found. In the CR-treated patients,
however, mean total scores showed only a small and not significant
further decrease in NYUPDS scores, reflecting a stable improvement of
the clinical condition at week 32 (5.2 ± 2.9) as compared with week 8
(5.5 ± 2.8). Rigidity and bradykinesia ameliorated, but not gait and
postural instability.
score
The mean (SD) total NUDS in all patients showed a statistically
significant decreased disability score after CR (week 8), but not after
STD-titration (week 4) compared with baseline scores (10.9 ± 5.2).
Scores and standard deviations decreased from 10.4 ± 5.3 at week 4 to
9.7 ± 5.3 at week 8. In the STD-treated patients a statistically significant
increase was found during the doubleblind phase, when total scores at
week 8 (9.9 ± 4.7) were compared with those of week 32 (10.9 ± 5.7). In
the CR-treated patients only small and not statistically significant changes
in disability were established when week-8 scores (9.3 ± 5.3) were
compared with the scores at week 32 (9.6 ± 6.1). Dressing and speech
gave the best responses.
Sa/e/y
There were no significant differences in laboratory values at both the
start and the end of the study. No changes in ECG recordings were seen
except for ischémie changes, in one STD patient, without clinical signs
and/or symptoms. During the open-label phase adverse effects, not
experienced earlier, were mentioned by 4 patients due to STD, and by 3
patients during the CR-titration phase, they consisted mainly of
gastrointestinal complaints (5) and hyperkinesia (2). Drug-related adverse
effects in the double-blind phase were also noted in both the
STD-treated patients (2, one with dizziness and one with dyskinesia) and
the CR-treated patients (gastrointestinal complaints (2) and hypotension
0))-
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Dosage and aose /re<7«ertçy (F/g. 2)
Mean (SD) total daily dosage of levodopa at baseline was 635 ± 290 mg
in 5.3 ± 2.5 mg doses, at week 4 - after STD titration - 619 ± 248 mg in
5.7 ± 2.5 mg doses, and at week 8 - after CR titration - the mean daily
intake was 822 ± 344 mg in 4.1 ± 1.6 mg doses. So, during the open-
label study, mean total daily levodopa intake in all patients showed a
significant increase during the CR-titration period, as compared with
baseline and week 4. Moreover, dose frequency declined significantly
during this period. In the patients treated with STD during the
double-blind period, mean daily levodopa intake (SD) and mean number
of doses (SD) at week 8 were 847 ± 325 mg in 4.1 ± 1.1 mg doses,
differing significantly from the figures at week 32: 663 ± 276 mg in 6.0 ±
2.6 mg doses. After the CR-titration period, daily dosage and doses did
not show major changes during prolonged double-blind CR treatment
over 24 weeks. Total levodopa intake was 797 ± 363 mg in 4.3 ±1.9 mg
doses at week 8, and 802 ± 345 mg in 4.5 ±1.6 mg doses at its end.
OPEN-LABEL
Figure 2. Mean daily levodopa
dosage and dose frequency with
SD in: 69 Parkinson patients at
baseline-I (BL)1,), week 4 (after
optimal STD titration) and week
8 (after optimal CR titration);
34 patients, treated double-blind
with STD, at baseline-2 (BL,:
week 8) and at week 32 (end of
the study): 35 patients, treated
double-blind with CR, at BL^
and at week 32. Significance:
wk 8 vs. BL, and wk 32 vs. BL,;
•P < 0.05, " P < 0.01: wk 8 vs.
wk4:"*'P < 0.01.
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Patients' diaries (Fig. 3, Table 2)
Figure 3. Mean total
daily on and off hours
and mean number of
daily off periods with SD
in: 69 Parkinson patients
during baseline-I (BLj),
week 4 (STD titration
period) and week 3 (CR
titration period); 34
p a t i e n t s , t r e a t e d
double-blind with STD,
during baseline-2 (BLj:
week 8) and week 32
(end of the study): 35
p a t i e n t s t r e a t e d
double-blind with CR,
during BLj, and week 32.
Significance: wk 8 vs. BL,
and wk 32 vs. BL,: " P
< 0.01: wk 8 vs. wk 4:
<**>P < 0.01.
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Table 2 Differences (A) of clinical efficacy scores (SD) during (left) open-label
Sinemet-STD (STD, wk 1-4) and Sinemet CR (CR. wk 5-8) titration: A STD = A
(BL1 - wk 4), A CR = (BL1 - wk 8): and during (right) double-blind treatment with
Sinemet-STD (STD. wk 8-32) or Sinemet CR (CR. wk 8-32): A STD = A (BL2 - wk
32), A CR = A (BL2 - wk 32).
NYUPDS
NUDS
On-hours
Off-hours
Off-periods
Open-label
A STD
0.57 ± 1.5"
0.46 ± 1.5
0.87 ± 2.4
0.92 ± 2.5
0.26 ± 1.5
A CR
1.51 ±
1.33 ±
1.49 ±
1.68 ±
1.58 ±
2 . 2 "
2 . 3 "
3 . 2 "
3 . 3 "
1.8"
A STD
vs
A CR'
*
*
*
Double-blind
A STD
0.83 ± 2.0*
1.00 ± 2.7*
0.70 ± 2.4
1.20 ± 2 . 3 "
1.10 ± 1.2"
A CR
0.31 Î 1.7
0.31 ± 2.7
0.84 ± 2.9
0.59 ± 3.2
0.07 ± 1.4
A STD
vs
A CR'
*
• •
'P-values indicating efficacy of Sinemet CR vs STD. Bold figures = positive
difference. NUDS = Nort-western University Disability Scale. NYUPDS = New York
University Parkinson's Disease Scale. 'P s 0.05: " P <; 0.01.
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The mean (SD) daily number of on-hours in all patients during the
open-label phase showed a statistically significant increase from baseline
(10.0 ± 2.7) to CR (week 8: 11.5 ± 3.1) but not in the STD dose-finding
period (week 4: 10.8 ± 2.3)). In the patients treated further with STD, a
statistically insignificant reduction was seen from CR week 8 (11.3 ± 3.3)
to STD week 32 (10.5 ± 3.0). In the CR-treated patients, the scores with
CR open-label (week 8: 11.8 ± 2.4) remained statistically unchanged
after the double-blind phase at week 31 (10.9 ± 2.2). The mean daily
number of off-hours during the open-label STD- and CR-titration in all
patients showed a significant decrease for CR in week 8 (4.8 ± 3.4)
versus STD in week 4 (5.6 ± 2.9). During double-blind STD-treatment,
the total off-hours in week 32 (6.2 ± 3.2) showed a statistically significant
increase compared with the number of off-hours with CR at week 8 (4.9
± 3.0). In the patients treated double-blind with CR, the number of
off-hours remained statistically unchanged from CR week 8 (4.7 ± 3.1) to
CR week 32 (5.2 ± 2.9).
A highly significant reduction in the daily number of off-periods was seen
during open-label periods at week 8 (3.3 ± 1.8), compared with both
baseline (4.9 ± 1.7) and week 4 (4.6 ± 1.8). In the STD-treated patients,
a highly significant increase in off-periods was seen between week 8 (3.5
± 1.6) and week 32 (4.6 ± 1.9). In the double-blind CR-treated patients,
no change in the number of off-periods was seen at week 32 (3.3 ± 1.7)
compared with week 8 (3.3 ± 1.8).
The total number of hours spent in bed at baseline was 7.6 h a day, and
did not change significantly throughout the study, neither during STD-
nor during CR-treatment. At week 32 the STD-treated patients spent 7.2
h and the CR-treated patients 7.8 h in bed. Actual sleeping time, quality
rating of sleep, and number of sleep interruptions did not change
significantly either during the study.
De/ay //j c//>i/ca/ response
The mean delay (SD) in levodopa-induced clinical effect was significantly
(P < 0.001) shorter after intake of Sinemet STD (45.3 ± 24.8 min) than
after Sinemet CR (64.4 ± 26.2 min).
overa//
Patient's perception of early-morning akinesia, dystonia, dyskinesia and
pain was regularly registered. During the open-label STD-titration phase,
perceptions showed no essential change compared to baseline. About one
third of all patients indicated a marked improvement of these symptoms -
except for pain (13%) - after CR-titration. After the 24-week
double-blind treatment period, 33% of the patients in both groups
treated with Sinemet-STD or Sinemet CR found their early morning
akinesia and dyskinesia to be improved. Dystonia was found to be
improved in 33% of the CR-treated patients but only in 18% of the
STD-treated patients. Improvement of pain was mentioned by 15% of all
patients during the double-blind phase. Most patients did not experience
any improvement or deterioration of these symptoms, but some felt
worse. Some STD-treated patients found their dystonia-related
complaints increased during the study period after stopping their CR
medication at week 8.
' and par/en£y' overa//
An appreciable number (80%) of 'blinded' physicians as well as
participating patients (64%), when asked for their opinion on the actual
medication (STD or CR) during the double-blind phase, indicated the
right drug.
Discussion
The increased clinical efficacy established according to NYUPDS and
NUDS in the Sinemet CR-treated patients suggests the existence of
increased intracerebral dopamine levels in the Sinemet CR patient group.
However, this conclusion is contradictory to the calculated bioavailability
of levodopa in both groups. Although a 33% higher dosage of levodopa
was administered with Sinemet CR than with Sinemet-STD, this higher
levodopa-CR dosage required for control of parkinsonian symptoms may
be attributed to its lower bioavailability (71%).'* Incomplete absorption
(incomplete disintegration of the polymer matrix) as well as increased
first-pass decarboxylation due to slow drug release may be responsible for
this decreased bioavailability.'* The major difference between the 2
dosage forms (STD and CR) appears to be that in Sinemet CR plasma
concentrations fluctuate within narrower ranges as a result of a lower
plasma peak and a higher end-of-dose level.*'" The CR formula thus
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ensures a more economic way of treatment by avoiding off-periods
induced by insufficient end-of-dose levels.
The improvement of efficacy was not obtained at the expense of an
increase in drug-related side-effects, not experienced earlier, in the
participating patients: side-effects were seen in a comparable degree in
both Sinemet-STD and Sinemet CR-treated patients, and consisted
mainly of gastrointestinal complaints. However. 3 patients dropped out
because of intolerable drug-related side-effects caused by Sinemet CR (2
due to gastrointestinal complaints, 1 to persistent dyskinesia).
As could be expected, the number of doses per day in the Sinemet
CR-treated patients decreased significantly by 28% from 5.7 to 4.1 after
the 4 week open Sinemet CR-titration period and remained more or less
at that level during the 24-week double-blind Sinemet CR treatment. So,
CR therapy not only stabilizes plasma levodopa levels as discussed above,
but also results in prolonged levodopa activity, which is more practical
and convenient for the patient. This prolonged levodopa effect after
Sinemet CR titration (4.1 doses at week 8) was lost during subsequent
double-blind treatment with levodopa-STD, which resulted in 6.0 daily
doses. The initial increase in number of daily doses during Sinemet CR
and the following increase after switching to Sinemet STD moreover,
shows that the difference in number of doses between Sinemet CR and
Sinemet-STD is due to different levodopa formulas and not to disease
factors.
The prolonged and stabilizing effects of Sinemet CR are only partially
supported by the on- and off-hour scores. The total number of on-hours
increased during the open-label, but not during the double-blind phase,
while the number of off-hours and off-periods decreased in both phases.
However, dystonia showed improvement in CR-, more than in
STD-treated patients (levodopa-induced dystonia mostly occurs as
end-of-dose phenomenon, its decrease should conform to an increase in
on-hours). Finally, the clinical (NYUPDS and NUDS) improvement
remained dependent on the type of levodopa formula administered
during the entire follow-up period (see above). These facts, together with
the knowledge that the number of on- and off-hours are associated with a
mutually exclusive outcome of the score, would of course predict a
corresponding increase in on-hours throughout the evaluation period. An
explanation might be found in the fact that the CR-treated patients spent
more time in bed (7.8 h versus 7.2 h in the STD-treated group of
patients).
Patients clearly noticed a delayed response (mean: 64.4 min) to Sinemet
CR as compared with Sinemet-STD (mean: 45.3 min). In our experience
SO
patients who broke their CR tablets in half for the first morning-dose
seemed to suffer less from this problem. This may be accounted for by
the increase of the absorption area and the consequent faster dissolution
and absorption, inducing an earlier rise to peak plasma levodopa levels.''*
The delayed response was the main reason why patients and doctors
quite easily guessed the correct nature of the drug during the
double-blind period. Accordingly, in 80% of the doctors and 64% of the
patients this study actually could not be called 'blind'! As mentioned in
the introduction, open studies showed better clinical efficacy of Sinemet
CR than did double-blind studies. Our findings led to the conclusion that
this discrepancy is not due to the factor 'open', because nearly all of the
patients could guess the code by the established delayed efficacy of a
dose of Sinemet CR.
Although individual patients unequivocally recognized Sinemet CR by
an increase of dyskinesia, the experience of dyskinesias was no reliable
indication for the nature of the drug: in all 3 groups, namely open-label
CR, double-blind CR, and double-blind STD, roughly one third of the
patients experienced an increase while another third experienced a
decrease in the severity of dyskinesias. As patients stated, the number of
off-periods diminished during treatment with Sinemet CR. In our
opinion, increase in dyskinesia during CR-treatment was noted in the
more seriously affected patients, probably due to their narrow therapeutic
window. Apparently, the emergence of dyskinesia depends on circumstan-
tial and disease factors rather than on the levodopa formula. This is
consistent with the findings of previous studies.*'*
This study confirmed that most efficacy variables demonstrated the
effect of Sinemet CR to be superior to that of Sinemet STD (see also
Table 2). It seems justified to suggest that these improved effects were
not achieved at the expense of an actual increase in total daily bio-
available levodopa, nor at the expense of safety and/or tolerability. The
superior effect of Sinemet CR as compared with that of Sinemet-STD
was established, not only in the open-label 4-week titration period but
also in the double-blind 24-week treatment period.
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CHAPTER 7
Parlodel SRO in Parkinson's disease: A double-blind
randomized comparison of Parlodel standard and
Parlodel SRO/
Jansen, A Staal-Schreinemacher, JJ van der Sande, JA Haas, JPWF Lakke.
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Introduction ; . ;
The role of dopamine agonists in the treatment of Parkinson's disease
(PD) is well established' and bromocriptine is widely used since the first
study on bromocriptine was published by Calne et al.* in 1974. To post-
pone and reduce long-term adverse effects of levodopa therapy, it has
become common practice to administer dopamine agonists in early stages
of PD/ Even its efficacy in de novo patients in combination therapy with
levodopa has been advocated recently.''
One of the major drawbacks of therapy with dopamine agonists is the
initial intolerance, contributing to a certain percentage of withdrawal. The
most frequent adverse effects are nausea, vomiting and orthostatic
hypotension, not always ameliorated by adjuvant therapy with dom-
peridone/ These side effects might, at least in part, be due to high and
rapid peak concentrations after oral administration or due to fluctuations
of bromocriptine plasma levels.
Parlodel SRO (slow release oral), a slow release form of bromocriptine,
has been developed in order to overcome these initial difficulties with
dopamine agonist tolerance. Parlodel SRO has a relative bioavailability
of 80% of the Parlodel standard (STD), but C^, plasma levels of Par-
lodel SRO are 50% lower, and T ^ values are increased from 30 min (for
Parlodel STD) to 7-8 h for Parlodel SRO. The half value duration time
for Parlodel STD is 3.5 h, and that of Parlodel SRO is 14.5 h.
Pharmacodynamic studies indicate significantly longer lasting inhibitory
effects on prolactin plasma levels [Sandoz, Basle, unpubl. data].
We carried out a randomized double-blind trial to compare the
tolerance and efficacy of Parlodel SRO versus Parlodel STD.
Patients and Methods
In the present study, a randomized double-blind, double-dummy design
was used to compare the tolerance and efficacy of Parlodel SRO and
Parlodel STD.
Thirty-four patients with idiopathic PD, who were treated with levodopa
from 4 to 24 months and received a stable optimized levodopa dosage for
at least 2 months prior to this study, gave informed consent. The study
population consisted of 17 men and 17 women, with a mean age 64.2
years (SD 11.3). The mean Hoehn and Yahr stage was 2.72 (SD 0.63),
the mean duration of PD was 4.8 years (SD 3.7) and the mean daily dose
of levodopa 394 mg (SD 216.8). The introduction of dopamine agonist
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therapy was considered justified as a method to improve the efficacy of
anti-PD therapy without increasing the levodopa dosage. None had
received a therapy with dopamine agonists previously. Excluded were
patients with a levodopa dosage exceeding 1,000 mg per day, i.e. Sinemet
1,100 mg: levodopa 1,000 mg + 100 mg carbidopa. Also excluded were
PD patients with severe adverse effects to 'long-term' levodopa therapy
(on-off phenomena and end-of-dose deterioration).
The patients were randomly allocated to two treatment groups:
levodopa and Parlodel STD or levodopa and Parlodel SRO. The study
had two phases. In the first phase, all patients were, if tolerated, titrated
via a fixed dosage regimen up to 15 mg daily of Parlodel in 6 weeks. In
the second phase, the test medication of either Parlodel SRO or Parlodel
STD remained constant over a period of 8 weeks. Levodopa dosage and
all other anti-PD medication remained unchanged throughout both study
periods. Patients were examined at 2-week intervals in the first study
phase, and thereafter at 4-week intervals.
Efficacy was assessed using the Unified Parkinsonism Rating Scale
(UPRS)', the Hoehn and Yahr scale', and the Schwab and England
Activities of Daily Living Scale.®
Global efficacy ratings and global tolerance ratings were performed at the
end of both study phases, i.e. an interim overall assessment at the end of
week 6 and a final overall assessment at the end of week 14. These rating
scales of different items were assessed by an investigator and by patients
and established a global rating of the item on a 5-point scale ranging
from very poor to very good (for tolerance) and from none to very good
(for efficacy). These scales were studied for statistical analysis by the
Mann-Whitney and the x^  test. Safety and tolerance were evaluated by
clinical assessment of signs and adverse events reporting. For statistical
analysis, the differences between the scores of baseline, 6- and 14-weeks
assessments of Parlodel SRO and Parlodel STD treatment groups were
calculated.
Results
The two groups of 17 patients each were well balanced at baseline with
respect to patient characteristics and disease severity, and there were no
significant differences between them. Also, the daily dose of levodopa
was the same in the two treatment groups.
Thirty of the 34 patients, who entered the study completed the 14-week
treatment period.
In 4 patients, adverse events necessitated discontinuation of the trial
medication. In the Parlodel STD group, 3 patients stopped Parlodel in
the first phase of the study, i.e. within the 6 weeks of the dosage titration
phase, because of palpitations, nausea and confusion. In the Parlodel
SRO group, one patient stopped Parlodel medication because of muscle
cramps. No other reasons for discontinuation were encountered.
In the 16 patients of the Parlodel SRO group completing the 14-week
trial period, the mean dose of Parlodel SRO was 11.7 mg; in the other
group, 14 patients ended the trial period with a mean dosage of 8.9 mg
Parlodel STD.
The magnitude of improvement from baseline in all major items of the
UPRS was comparable in both groups, and there was no statistical
difference between both study groups in all the tests of the UPRS (fig.
1). The UPRS items on dyskinesias after supplementing levodopa therapy
with a maximum dosage of 15 mg of Parlodel showed no appearance of
or improvement in dyskinesias.
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Figure 1. Mean total scores, items 1-43 summed scores of UPRS in the Parlodel STD
(—) and Parlodel SRO ( ) groups. Standard deviations are given in parentheses.
The Hoehn and Yahr and the Schwab and England assessment data
slightly suggested a tendency in favour of the SRO group. The patients
mean global ratings of efficacy had a slight trend in favour of Parlodel
SRO, but this reached no statistical significance (fig. 2).
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Figure 2. Global efficacy ratings (14-week assessment) by patients of Parlodel STD
( | ) and Parlodel SRO ( | ). 4 drop-outs were excluded.
Figure 3. Global tolerance ratings (14-week assessment) by patients of Parlodel STD
( | ) and Parlodel SRO ( | ). 4 drop-outs were excluded.
Side effects, recorded as definitely due to study medication, occurring in
both groups were mainly: nausea, stomach pain, confusion, hallucinations
and orthostatic hypotension. No specific side effects were occurring less
frequently in the Parlodel SRO group. Statistical evaluation, however, of
all comparisons by means of the Mann-Whitney test showed an overall
reduction in the incidence of side effects in the Parlodel SRO group. The
global tolerance ratings performed at the end of both treatment periods
(6 and 14 weeks) were the other basis for assessing severity and
frequency of side effects and are shown in figure 3. The difference in the
two treatment groups was not statistically significant at the 0.05 level, but
the trend was in favour of the Parlodel SRO group. This trend was
already reached at the 6-week assessment of global tolerance rating and
stabilized at the final 14-week assessment.
Considering efficacy and tolerance together, Parlodel SRO appeared to
be significantly superior to Parlodel STD in the patient assessment (x':
6.58, p < 0.02), whereas there was no significant difference in the investi-
gator assessment.
Discussion
Our results indicate that the new galenic formulation of Parlodel, i.e.
Parlodel SRO, reduces initial adverse events. This is in accordance with
the peripheral pharmacokinetic profile of Parlodel SRO, by which high
peak plasma concentrations after oral administration of this dopamine
agonist are prevented.
The efficacy of Parlodel SRO and Parlodel STD was the same.
Especially the results of the UPRS analysis showed complete comparable
results, even though the relative bioavailability of Parlodel SRO is
somewhat less. The patient assessment of overall efficacy and tolerance -
analyzed together - was significantly better in the Parlodel SRO group.
Taken together, these figures of efficacy and tolerance suggest that with
Parlodel SRO more PD patients derive benefit from a drug that they are
able to tolerate in an optimal dosage. One of the major drawbacks of
dopamine agonist therapy can hence be reduced. As a consequence of
these results, another advantage of Parlodel SRO could be the more
rapid titration to an effective dosage. In addition, the frequency of drug
administration of Parlodel SRO may possibly be reduced on the basis of
its pharmacokinetic profile permitting improvement in patient com-
pliance, the willingness to continue (supplemented) therapy and at the
same time a more stable clinical response.
These improvements in the use of bromocriptine for the treatment of
PD are currently being evaluated.
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CHAPTER 8
A. "Old wine in new bottles"; therapy with
subcutaneous apomorphine in Parkinson's disease.
B. Pharmacokinetics of apomorphine in Parkinson's
disease. Plasma and cerebrospinal fluid levels in
relation with motor responses.
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"Old wine in new bottles"; therapy with subcutaneous
apomorphine in Parkinson's disease/
The medical treatment of the symptoms of Parkinson's disease has the
last decennia been based on levodopa-substitution. Pharmacologically this
disease can be characterized as a syndrome that arises as a consequence
of dopamine-deficiency in the nigrostriatal system. The orally
administered levodopa is, after résorption into the gastro-intestinal tract
and after passage through the Blood Brain Barrier (BBB) transformed in
the nigrostriatal neurones into the effective dopamine.
Mostly the oral levodopa is combined with a peripheral DDI which does
not pass the BBB. There are indications that this combination may
contribute to the late side-effects of the usually successful therapy.'
Levodopa is of late years preferably in an early phase combined with
dopamine-agonists like bromocriptine and pergolide, in order to prevent
complications of the levodopa therapy at long-term. These complications
exist above all from dyskinesia and alternating episodes of hypokinesia
and hyperkinesia, so-called response fluctuations.
Recently a method has been introduced in which dopamine-agonists are
administered subcutaneously. The time-honoured and antique
apomorphine appeared to be effective herein. The beneficial effects can
be obtained by repeated subcutaneous injections (for example using an
injection device as used with insulin therapy of diabetes mellitus) or by a
continuous subcutaneous pump. Both these therapy forms are discussed
in the light of case histories.
Patient A, a 56-years-old woman, has had Parkinson's disease for 10 years
and has been treated with levodopa for 8 years. On account of a slow
progression of the hypokinesia and a disturbed postural stability a
dopamine-agonist was added to levodopa 2 years ago. As well
bromocriptine as pergolide, in low dosage of respectively 15 and 1.8 mg a
day, caused the patient complaints of orthostatic dizziness and visual
hallucinations. The present treatment consists of 6 tablets of levodopa
with decarboxylase inhibitor, distributed over the day, with a total daily
*"E.N.H. Jansen en T. van Laar. "Oude wijn in nieuwe zakken"; thérapie met
subcutane apomorfine bij de ziekte van Parkinson. Ned Tijdschr Geneeskd
1990; 143( 18):889-891.
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dosage of 350 mg. With this medication there still were a lot of problems,
especially in the afternoon: increase of tardiness of movement, tremor
and unsteadiness in walking, and above all starting-problems. These are
so-called 'off-phenomena, which indicate 'wearing-off of levodopa.
Besides there were dystonic phenomena at the right foot in the course of
the afternoon, with cramps in the right calf, the so-called 'off-period'-
dystonia. These off-phenomena in the afternoon, which often appeared at
irregular times and which could well last for half an hour per episode,
appeared to respond excellently at subcutaneous injections with
apomorphine. The injections were administered with the help of a
subcutaneous injection device, such as used in insulin therapy of patients
with diabetes mellitus.
Nowadays the patient's husband, formerly a textile-worker, administers
the injections. The dosage of apomorphine is 2 mg a time, solved in 0.2
ml; the point of time of administration depends on the appearance of the
off-phenomena. On an average this patient makes use of these injections
twice in the afternoon or in early evening hours. The apomorphine
becomes effective after about 10 minutes; the patient always feels this
coming by indomitable yawning. The duration of efficacy is about 90
minutes. There are not any side-effects; at first domperidon was
prescribed against nausea, but later on this did not seem to be necessary
any more. The dosage of levodopa is unaltered. Patient has now been
treated with apomorphine very successfully in this way for almost one
year and a half and she is very satisfied with the beneficial injections. In
this way apomorphine injections mean to her preservation of
independence in daily life.
Patient B, a 74-years-old man, has had Parkinson's disease for 20 years
now. At first only a tremor was troubling him, which was formerly
diagnosed as an essential tremor, an affection that occurs in his family as
appears from the anamnesis. Later on more phenomena appeared,
namely a tremor combined with rigidity and starting problems. Moreover,
he could no longer turn around in bed very well any more. He had been
treated with 125 mg levodopa (with decarboxylase inhibitor) 8 times a
day for 6 years. The last 2 years there had been severe fluctuations in
mobility: after each administration of 125 mg levodopa a beneficial effect
was no longer than one hour perceptible. Besides a striking quantity of
abnormal involuntary movements was provoked rather soon after the
onset of efficacy of this dosage - especially dyskinesia in the face - which
usually lasted until the levodopa had become ineffective again. Such
dyskinesia are called peak-dose dyskinesia, because of the presumed
connection with the peak-level of plasma levodopa. Decrease of the dose
of levodopa to 90 mg per gift led to decrease of peak-dose dyskinesia,
but at the same time reduced the duration of efficacy to half an hour and
also provoked painful cramps in the calves in the next 'off-period'.
Test treatment with Madopar HBS, a compound with slow release,
failed: there was an intolerable increase in intensity of the dyskinesia.
For 12 months this patient is treated with a subcutaneous pump for
infusion of apomorphine in a dosage of 3 mg per hour. The total daily
dose is 25 mg. Infusion takes place from 9 a.m. to 11 p.m. The
subcutaneous needle is applied by the patient's wife, a former psychiatric
nurse. She had some difficulty to come to see that administration of
apomorphine to her husband would not constantly provoke nausea and
vomiting, as she was used to in psychiatry.
Dyskinesia have not occurred any more and the total number of 'off-
hours' per day has been reduced from 4 to 2 hours, with a constant dose
of levodopa. During the first three weeks there was a painful itching
panniculitis at the place of insertion of the subcutaneous needle for
infusion, which has to be changed every 24 hours. Nausea could be
effectively fought by domperidon; later on this remedy did not necessarily
have to be taken any more.
Patient C, a 27-years-old man, schoolmaster of profession and a fanatic
wooden-ball-shooter (in Twente called 'klootschieter') - a popular sport
in the Eastern part of Holland - has suffered from Parkinson's disease for
7 years. This malady started with a tremor at his right hand and arm, and
increased during the following years with severe hypokinetic-rigid
phenomena at his right arm and leg. For 5 years this patient has shown
an excellent beneficial response to levodopa-treatment. A beforehand
discussed stereotactical - surgical procedure was unnecessary, because
tremor responded so favourably to levodopa-therapy. Former amantadine
primidon and propanolol had proved to be ineffective. However, after
one year of levodopa therapy severe dyskinesia developed likewise in
right arm and right leg, which occurred at low dosage levels: each tablet
of Sinemet 62.5 mg (50 mg levodopa and 12.5 mg carbidopa) brought
about severe dyskinesia. These generally occurred from half an hour after
onset of efficacy of Sinemet until the end of efficacy. So also with this
patient we can speak of peak-dose dyskinesia. The total daily dose was
562.50 mg, distributed over 9 dosages. Test-treatment with dopamine-
agonist pergolide (Permax) was totally ineffective on duration of response
or adverse events of levodopa.
Subsequently, patient was treated with apomorphine with the use of a
subcutaneous infusion pump. The infusion daily takes place from 7.30
a.m. to 11.30 p.m. with a constant speed of 2.5 mg per hour. The dosage
of Sinemet could subsequently be reduced to 7 times 62.5 mg a day. The
initial severe response-fluctuations with peak-dose dyskinesia provoked by
levodopa therapy could thus be ameliorated by apomorphine much to the
satisfaction of patient and his wife. Almost all day he was able to
function unhindered. Objectively speaking, there are still some
generalized involuntary choreo-athetotic movements, but these are not
found to be inconvenient for the patient. His fellow wooden-ball-shooters
have told him more than once that he is looking so much more cheerful
and vivacious and that he takes the track in much shorter time. These
involuntary movements will undoubtedly have contributed to these
effects.
At the moment patient has been treated with the apomorphine pump for
1 year without side-effects.
Ladies and gentlemen, diagnosis and medical treatment of Parkinson's
disease have always been matters for which special skills are necessary.
The beneficial response of levodopa therapy, which can be brought about
in 70% of patients with Parkinson disease makes this therapy look
simple. This completely changed when it was made clear that levodopa
therapy after some years is complicated by severe adverse events such as
dyskinesia and response fluctuations." There are some strong arguments
that these phenomena - at least partly - are a consequence of its own: by
the short half-life of levodopa after oral administration response
fluctuations and dyskinesia can be induced - considered purely
pharmacokinetically.^ A continuous intravenous administration of
levodopa has a beneficial effect on these phenomena* and thus confirms
the above mentioned pharmacokinetic mechanism. In clinical practice this
intravenous administration is, however, difficult to realize. Consequently
there came an interest in subcutaneous continuous application of the
dopamine-agonists lisuride and apomorphine." In a technically relatively
simple way the problems raised by long-term levodopa therapy can be
attacked. Because the ratio between magnitude of response and adverse-
events of apomorphine is considerably higher than that of lisuride,
apomorphine is preferable."
Psychiatric side-effects only seldom occur, above all in the absence of
previous psychiatric history/' The infrequently appearing nausea is
effectively fought or prevented by domperidon. With continuous infusion
of apomorphine the provocation of nausea or the stimulation of the area
postrema seems to be not very substantial, at least in comparison to the
nausea after oral application. In former days apomorphine was used as
an emetic. Long-term oral administration of apomorphine can cause
renal dysfunction.''" This side-effect is not found after subcutaneous
application of apomorphine. At the simultaneous use of an oral
compound against nausea such as domperidon a relatively safe combined-
treatment has been made possible.
A major problem with the subcutaneous infusion of apomorphine,
however, is the panniculitis. From the fact that subcutaneous infusion
with insulin is not complicated by panniculitis, can be concluded that not
the infusion-needle itself, but apomorphine is responsible for this
subcutaneous inflammation. Therefore, it is advisable to maximize the
concentration of apomorphine in the infusion liquid to 2% (20 mg
apomorphine per ml). This is in accordance with the experience of
others.^
Of the 14 patients with Parkinson's disease, thus treated with
apomorphine, 2 had to be withdrawn from therapy as a consequence of
this panniculitis. Treatment with apomorphine injection-pen is not
complicated by this panniculitis.
Finally, we are obliged to mention the psychic stress associated with the
treatment of a subcutaneous infusion pump: by the infusion the patient
is, as it were, transformed into a puppet on a string. For some patients
this literal lack of freedom was unacceptable or even indisputable.
The apomorphine already known for so many decades as an emetic",
can now play an essential and pivotal role as a dopamine-agonist in cases
of therapy-refractory response-fluctuations in Parkinson's disease.
We are very grateful to professor Jan van Gijn, neurologist at State
University of Utrecht, for this critical and so very kind comments.
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B. Pharmacokinetics of Apomorphine in Parkinson's
Disease. Plasma and Cerebrospinal Fluid Levels in
Relation with Motor Responses.'
Introduction >.•
Apomorphine is a potent dopamine agonist which is used as diagnostic
tool and therapeutic drug in patients with Parkinson's Disease (PD).
Therapeutically apomorphine has proved to be an effective drug in the
management of motor fluctuations in PD. '" Apomorphine is used
diagnostically in response tests to distinguish dopa responsive from non-
responsive patients and consequently to distinguish Idiopathic Parkinson's
Disease (IPD) from Parkinsonian Plus Syndromes (PPS).^
In clinical practice apomorphine is given subcutaneously, sublingual or
intranasal." Since apomorphine is quickly metabolized by the liver, oral
administration is not sensible. Subcutaneously administered apomorphine
is avoid of this high first-pass effect and has a short latency of onset
(about 10 minutes) and a medium time of duration (about 90 minutes) in
dopa-responsive PD patients. These features make apomorphine an
extremely promising therapeutic modality as a patient-dosed drug for off-
periods and severe response fluctuations in PD.
There have been several studies in which the peripheral pharmacokinetics
of apomorphine have been investigated, by means of blood samples.''*
However the central pharmacokinetics of apomorphine, up to now, are
unknown. Only in a study with monkeys the central pharmacokinetics
have been investigated by taking cerebral spinal fluid (CSF) samples.'
Because the plasma levels of apomorphine in humans do not correlate
with the motor effects, we wanted to investigate the central
pharmacokinetics of apomorphine. As has been described with levodopa,
the levels in CSF might better explain the motor effects than the levels in
plasma."' Therefore we measured apomorphine levels in plasma and CSF
samples of PD patients and correlated them with the clinical motor
responses.
Our hypothesis was that a two compartment pharmacokinetic model, with
a central and peripheral compartment, would better explain the clinical
'DJ Hofstee, C Neef, T van Laar, ENH Jansen. Clin Neuropharmacol 1994:17:45-
52.
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responses compared to a one compartment model. The central
compartment includes the brain with CSF, whereas the peripheral
compartment contains the remainder of the body.
Methods
We studied two PD patients, patient A is a de novo PD patient and
patient B is a patient with advanced PD. The study was approved by the
Medical Ethical Committee of our hospital and both patients gave their
informed consent. The characteristic data of these patients are given in
table I.
Table I. Clinical data of studied PD patients.
Patient A Patient B
Age 48 years 64 years
Sex (m/f) f f
Duration PD 1 year 7 years
Hoehn & Yahr II (grade I-V) V (grade I-V)
Webster score 5 (max. 30) 20 (max. 30)
To prevent adverse events of apomorphine, like nausea and hypotension,
domperidone 60 mg/day was orally administered. The customary anti-
parkinson medication of patient B was discontinued before the rfose-
y/rtd/>2£ test and the p/zarmaco/c/>zeftc test were done. Patient A did not use
any anti-parkinson medication.
The day before the p/iarmaco/a/îe/ic test an apomorphine do$e-///irf«jg test
was done, as described by Hughes et al/ The patients received rising
doses of apomorphine subcutaneously, until they had an optimal positive
motor response. Patient A responded with 5 mg of apomorphine and
patient B with 3 mg of apomorphine.
During the p/2armaco/c/«e//c test blood and CSF samples were taken at
t = 0, 10, 20, 30, 45 and 60 minutes after administration of the
responsive dose apomorphine. For patient B also at t = 90 minutes
samples were taken. The blood samples, 4 ml, were drawn from an
intravenous canula and the CSF samples, 2 ml, from a lumbar spinal
catheter. After the test the patients received an epidural blood patch to
prevent post lumbar puncture complaints.
Clinical scoring of the motor responses in the dore-/îrcrfmg test and the
/00
test was based on the results of the scores of the finger
tapping test during 30 seconds and of the modified Webster Rating Scale
(WRS), existing of ten items." These scores were also taken at t = 0, 10,
20, 30, 45, 60 and 90 minutes.
The samples of plasma and CSF were kept on ice during the test and
centrifugated and frozen after the test. The levels of apomorphine in
plasma and CSF were determined by a method using high-performance
liquid chromatography with electrochemical detection.'°
The data were analysed statistically by means of the correlation formula.
The level curves were fitted and analysed with the computer programs
MW/PHARM and PH/EDSIM to construct a pharmacokinetic model."
Results
C7/n/ca/ motor responses:
In patient A with an initial WRS score of 5, extrapyramidal motor signs
started to improve within 10 minutes, later her tremors and rigidity
diminished completely. Her maximal improvement on the WRS was 3
points. After about 90 minutes her tremors and rigidity started to return.
Patient B with an initial WRS score of 20 started to improve within 20
minutes. Rigidity decreased and the tremors diminished completely. Her
maximal improvement on the WRS was 5 points. After 90 minutes the
tremors started to return.
The absolute improvements on the WRS of patients A and B are shown
in figures 1 and 2 in relation with apomorphine plasma and CSF levels.
During the test patient B had complaints of nausea but no hypotension.
Patient A had no adverse effects. In both patients no post lumbar
puncture complaints were registered.
CSF apomo/p/z/Vze /eve/s:
In figures 1 and 2 the apomorphine levels in CSF and plasma are
depicted for patients A and B. The data points were fitted with the
MW/PHARM and PH/EDSIM programs and these calculated curves are
also shown.
Serum (ng/ml)
so-,
Improvement (points)
30 40 SO
Time (mln)
Figure 1. Clinical motor responses, CSF and plasma levels after 5mg apomorphine s.c.
in patient A.
Table II. Apomorphine pharmacokinetic data of studied PD patients.
Initial close
C a^^  plasma
T,,,a* plasma
AUC plasma
C » , CSF
Tm,v CSF
AUC CSF
Patient A
5 mg
47.8 ng/ml
10 min
640 ng-hr/ml
1.72 ng/ml
30 min
29.9 ng-hr/ml
Patient B
3 mg
21.5 ng/ml
20 min
268 ng-hr/ml
0.53 ng/ml
30 min
17.7 nghr/ml
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The maximal concentration C^,, the time to reach the maximal concen-
tration T^^ and the area under the curve AUC, were calculated for the
apomorphine levels in plasma and CSF. The results are shown in table II.
Serum (ng/ml) CSFfng/ml)
0,6
Legends
Improvement (points)
Figure 2. Clinical motor responses, CSF and plasma levels after 3mg apomorphine s.c.
in patient B.
The ratio between the Q,^ of apomorphine in CSF and plasma is for
patient A 0.036 and for patient B 0.025. The ratio between the AUC of
CSF and plasma apomorphine levels is 0.047 for patient A and 0.066 for
patient B.
The time lag between the T^, of apomorphine in plasma and in CSF was
20 minutes for patient A and 10 minutes for patient B.
703
The correlation between the clinical motor responses, WRS score
improvement, and the apomorphine levels in plasma were for patient A
+ 0.47. and for patient B +0.25. The correlation between the clinical
motor scores and the apomorphine levels in CSF were for patient A
+ 0.93. and for patient B +0.89. Apomorphine levels in CSF thus seem to
correlate more appropriately with clinical effects than apomorphine
plasma levels.
The tapping scores did not correlate with apomorphine plasma and CSF
levels or the WRS scores.
model:
Based on aforesaid data, a pharmacokinetic two compartment model can
be constructed for patient A and B. This is demonstrated in figure 3. The
first compartment characteristics are based on the plasma levels and the
second compartment characteristics on the CSF levels. With the
MW/PHARM and PH/EDSIM programs we calculated the values of the
parameters for this model, which are shown in table III."
I k01
k 12
k21
k10
Figure 3. Two compartment pharmacokinetic model (Vj = compartment one,
compartment two, K^, K ^ K ^ K ^ , = exchange constants)
The parameters of the model are the peripheral volume of distribution
(the first compartment): V,, the central volume of distribution (the
second compartment): Vj and the exchange constants: K<,i, K,o, K,j and
K2,,.
Table III. Parameters apomorphine two compartment pharmacokinetic model of
studied PD patients.
Patient A Patient B
V, (plasma) 54 1 95 1
V2(CSF) 7111 1025 1
koi 7.5 /hr 5.5 /hr
k,o 1.4 /hr 1.1 /hr
ku 2.6 /hr 1.1 /hr
kj, 4.2 /hr 2.7 /hr
Levé/ - e/fecf
For these two patients we calculated the relationship between the
apomorphine CSF levels and the effect, the motor response improvement
as percentage of the maximal possible motor improvement on the WRS.
This was done according to the Hill equation and based on the fitted
apomorphine CSF level curves. The level - effect curves for patients A
and B are shown in figure 4.
Discussion
Up to now the central pharmacokinetics of apomorphine in humans were
unknown. We studied the central and peripheral pharmacokinetics of
apomorphine in two PD patients and measured the relationship with the
clinical motor responses.
The levels of apomorphine in CSF were substantially lower than in
plasma, the ratio C^CSF) / C^,(plasma) was 0.036 for patient A and
0.025 for patient B. Apomorphine T^(CSF) values were 20 and 10
minutes longer than corresponding T^,(plasma) values in the two
patients.
The correlation between the levels of apomorphine and the motor
responses (WRS improvement) was low for the plasma levels but high for
the CSF levels. For patient A this correlation was respectively 0.47 and
0.93 and for patient B 0.25 and 0.89. The clinical motor responses after
apomorphine administration thus seem to correlate much better with
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60%-
40%-
% of max. motor
— i — i
improvement
/
/
Relationship:
Paripnt A
Patient B
0.2 0.8 0.8 1 1.2
CSF level (ng/ml)
1.4 1.8
Figure 4 Relationship between the apomorphine CSF levels and the motor response
improvement as percentage of the maximal improvement on the WRS.
CSF apomorphine levels than with plasma apomorphine levels.
We conclude that a two compartment pharmacokinetic model better
describes the clinical effect of apomorphine than a one compartment
model. This confirms our presumed hypothesis.
The timed finger tapping test scores did not correlate with apomorphine
plasma or CSF levels or with WRS improvement scores. We have no
obvious reasons for this lack of correlation. But it is not impossible that
this test was less accurate to reflect the motor status of these two patients
because of distraction of attention and patient's position with a lumbar
spinal catheter in situ.
We studied the levels of apomorphine in lumbar CSF only, and
consequently cannot rule out the possibility that the results of a study
with ventricular CSF are different from this study. But because
apomorphine appears rapidly in the lumbar CSF and the levels of
apomorphine in the lumbar CSF correlate strongly with the motor
responses, the difference probably will not be substantial.
To construct a pharmacokinetic model, which can be used to advice
clinicians to apomorphine dose administration for PD patients, more
patients need to be studied to calculate population parameters.
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CHAPTER 9
Increase of Parkinson disability after fluoxetine
medication.®
"E.N.H. Jansen. Neurology 1993;43:211-213.
oc
Introduction
Depressive symptoms and major depression are major clinical features of
Parkinson's disease (PD). The mean value of depressive symptoms in PD
is 86%, and 37% for major depression.' The pathophysiology of this
affective disorder in PD is largely unknown. Dopaminergic deficiency has
been postulated, with neuroanatomic representation in the dopaminergic
mesolimbic pathways or a dopamine depletion in the prefrontal cortex."
Serotonin allegedly is involved in the pathophysiology of depression, with
a substantial deficiency of serotonin content and of serotinergic cells in
the dorsal raphe nucleus in patients with PD and depression.' Also, a
norepiphrine depletion is found to be involved in mood and motor
disorders, as well as in cognitive function impairment, demonstrated in
the brainstem and particularly in the locus coeruleus.'' It is unlikely that
depression in PD is reactive; the high frequency of depressive symptoms
and episodes in the presymptomatic phase of PD is a solid argument
against this reactive hypothesis. ••'•' " • ' • « * • • > - - > *
Patients with PD and depressive symptoms consequently are frequently
treated with antidepressants. The serotonin reuptake inhibitor fluoxetine,
a relatively new antidepressive compound, seems a promising drug to
overcome the affective problems in PD patients. Recently, extrapyramidal
side effects of fluoxetine in psychiatric patients have been documented.''"''
We describe four patients with PD and long-standing stable levodopa
therapy in whom the PD disability deteriorated during fluoxetine
exposure.
Case report. Four patients with PD meeting DSM-III criteria^ for major
depression had severity of depression estimated on the Hamilton
Depression Rating Scale (HDRS-17 items)." In all four patients,
treatment with fluoxetine was considered justified on the basis of their
scores on HDRS. Patient data are summarized in the table. >«'?«^"Cirrnj^
Antiparkinson medication consisted in all patients of levodopa
( +D.D.I.) and amantadine. No monoamine oxidase inhibitors were used.
Cognitive impairment was not present in these patients. Fluoxetine
dosage was 20mg/d in all four patients. Antiparkinson medication was
kept unchanged 2 months prior to and during fluoxetine treatment.
Patients were not allowed to use neuroleptics, tranquillizers, hypnotics,
and/or other medication relevant to depression or PD during this
observation period.
Patients tolerated fluoxetine without problems, i.e., no cardiovascular or
gastrointestinal adverse effects. Patient number 2, with a prior history of
migraine, had atypical vascular headache episodes only in the 2nd month
of fluoxetine treatment. In no patient were depressive symptoms
substantially alleviated by fluoxetine (see table of scores of HDRS).
Fluoxetine was given to the patients for at last 8 weeks, with a maximum
of 11 weeks. Parkinson disability definitely increased, as spontaneously
reported by three patients and substantiated in all four patients with the
UPDRS scores (see table). Symptoms on UPDRS (part Ill-motor
examination)' that were most frequently increased were tremor at rest,
fingertaps, hand movements, and body bradykinesia. Patient number 4,
without prior rest tremor, developed a tremor at rest in both hands that
was marked in amplitude and present most of the time. None of the four
patients had an increase in action or postural tremor in the hands. The
increase in the fingertap and hand movement scores was more than one
point in three of the patients. Signs and symptoms of increased Parkinson
disability became evident 10 to 14 days after starting fluoxetine.
Fluoxetine was withdrawn from all patients, and a return of UPDRS
scores to previous values was established within 4 weeks. An analysis of
variance of the HDRS ratings revealed no significant differences between
the three instances of measurement (F[2.6] = 0.487; p = 0.637). Before,
during and after fluoxetine exposure, the mean ratings were 21.75 (SD
4.11), 20.50 (SD 3.32), and 21.25 (SD 5.85). : ,..;•= ^r , , ' ; , n -.-./••, .,
Despite the small number of patients, there is a significant "time" effect
for the UPDRS ratings (F[2.6] = 51.92; p = 0.0001). Paired t tests
disclosed that with fluoxetine the UPDRS ratings were significantly
higher than both before and after fluoxetine exposure. The ratings of
UPDRS before and after fluoxetine did not differ significantly (t[3] =
1.73; two-tailed, p = 0.18).
In patient number 4, the severe rest tremor in both hands improved
dramatically on intranasal apomorphine application (3 mg). Prior to
apomorphine administration, this patient was pretreated with
domperidone 60 mg/d. For 3 weeks, this apomorphine treatment -
intranasal and on demand - was realized with substantial benefit after
withdrawal of fluoxetine.
In patient number 2, fasting plasma prolactin levels increased up to
1,200 mU/1 after 4 weeks of fluoxetine treatment. Six weeks after
fluoxetine withdrawal, the fasting prolactin level was normalized, i.e., 280
mU/1. In the other three patients, no change in plasma prolactin levels
could be established. Otherwise, laboratory results in all patients were
normal.
7/2
Table
Patient data
2 riîiv*
•sfin îonnu'ï aW .m-
Patient
1
4 ; ïnj-;-^.
Mean+SD
Age
(JT)
56
61
52
• • ; ' • • : 5 4
55.57 + 3.86
Duration
PD
OT)
5
7
3
8
5.75 + 2.22
Hoehn &
Yahr
stage
III
II
II
m
UPDRS*
28 41 30
17 29 20
23 31 22
11 19 13
Levodopa
HDRS* dose
a b c (mg/d)
23 31 24
18 16 15
27 24 28
19 21 18
440
750
375
990 '>*Li
638.75 + 285.67
'Scores of UPDRS (Unified Parkinson's Disability Rating Scale-part Ill-motor
examination) and HDRS (Hamilton Depression Rating Scale-17 items), a = before, b
= during, and c = after fluoxetine exposure . , . , . . . . . . . . ,
Discussion
PD is a striatal dopamine deficiency syndrome that can be mimicked to a
very large extent by MPTP exposure. The postsynaptic dopamine
depletion in the basal ganglia can also be produced by chronic
neuroleptic medication.
The four patients in this report with major depression had a
deterioration of Parkinson motor performance after exposure to
fluoxetine. The increase of Parkinson signs and symptoms was transient
in all four patients, i.e., they did not improve until after withdrawal of
fluoxetine. The reversibility of this deterioration contradicts the possibility
of natural progression of PD during the period of fluoxetine medication.
The antidepressive efficacy of fluoxetine was not found to be substantial
in these four patients. The antidepressant efficacy of fluoxetine in PD
patients cannot be generalized because of the small number of patients in
this study, the modest dosage of 20 mg/d of fluoxetine, and the apparent
severity of depression in these four patients. The prevalence of the
phenomenon of decrease of motor performance and/or improvement in
depression in PD patients is not given in the literature and cannot be
estimated on the basis of our small personal experience.
We are aware of the inadequacies of using HDRS in PD patients since
symptoms of PD may overlap with those of depression.' In this case
report, however, the transient change in UPDRS scores was considerable
and could not be attributed to other causes. The increase of Parkinson
disability after fluoxetine exposure can easily be explained on the basis of
a dopamine-antagonistic activity of fluoxetine.' The increase of prolactin
/ / i
plasma levels in one patient is in accordance with this'°, as is the benefit
of apomorphine in another patient. We cannot rule out other possibilities
for this unwanted effect of fluoxetine.* Recently, the manifestation of
Parkinson features in depressed, non-parkinsonian patients after
fluoxetine exposure has been published.''"* We are not apprised, however,
of the striatal dopamine functioning in these patients, which could have
been achieved by fluorodopa PET to exclude a presymptomatic Parkinson
phase in these depressed patients. On the basis of our observations, the
use of fluoxetine as a serotonin reuptake inhibiting antidepressant in
Parkinson patients with depression seems to warrant some caution. —
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CHAPTER 10
Clozapine in the treatment of tremor in Parkinson's
disease."
"ENH Jansen. Acta Neurol Scand 1994;89:266-269.
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Introduction
Clozapine is an atypical antipsychotic drug in the dibenzodiazepine class,
and has been used since 1971 in the treatment of hard to-treat
schizophrenic patients.' Clozapine is an atypical neuroleptic drug, because
its propensity to provoke extrapyramidal side effects is only very weak.
On the basis of this pharmacological profile Clozapine has proved to be a
very effective neuroleptic agent in psychiatry. The addition of Clozapine
in the treatment of psychosis in Parkinson's disease (PD) is another ideal
indication for this compound. "
The use of Clozapine in the treatment of tremor in PD has only rarely
been subject of study.*•*•'
We studied the addition of Clozapine in 23 patients with PD and optimal
antiparkinson medication, who all had as major disability a troublesome
tremor - and investigated the antitremor efficacy and tolerability of
Clozapine.
Patients and Methods
Twenty-three patients with PD and, despite optimal antiparkinson
treatment, a troublesome tremor, participated in this study. All patients
signed informed consent documents, in which special reference was given
to agranulocytosis as the major adverse event of Clozapine.' The study
was approved by the hospital's Ethical Review Board. The study was
conducted in a open-label design. Capsules contained 6.25mg. Clozapine.
The dosage of Clozapine was very gradually increased: all patients started
with one capsule ante noctum; further increase - if necessary - was
established every third day and the daily dosage was given in the early
morning and antenoctum. No upper limit of daily dosage of Clozapine
was set. The study duration was 6 months. Patients with a positive effect
of Clozapine on tremor scores could make a choice to proceed with
Clozapine therapy. i- t.
Patients were evaluated at two weeks visits, blood counts were performed
on a weekly basis. At 4 weeks intervals the UPDRS," motor exam score
(items 18-36) was evaluated. Adverse events were recorded each second
visit; special attention of adverse events was given to sedation, hypoten-
sion, epilepsy and hypersalivation. Sleep benefit and improvement of
dyskinesias were also scored.
Antiparkinson medication was not changed during the whole period of
study. If sedation was a major feature in the first weeks of the study -
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PD patients with a psychosis in history or at present were excluded, as
were patients with vivid dreaming. Also excluded were PD patients with
overt dementia (score on Mini Mental State Exam less than 18 points),
and with a history of another neuropsychiatrie illness. A paired t-test was
used to see whether the total scores on UPDRS after exposure to
Clozapine were significantly lower than before exposure. The same
analysis was reported for the tremor subscores and for the 'non-tremor'
subscores on the UPDRS. In order to detect a possible relationship
between the dosage of Clozapine and the change in the (sub)scores on
the UPDRS, Kendall's tau was computed.
Table 1. Summary of cases
put
nr
1
2
3
4
5
6
7
8
9
10
II
12
13
14
IS
16
17
18
19
20
21
22
23
* À
It
54
61
72
68
49
75
73
61
57
43
70
79
54
63
69
53
59
72
66
48
56
78
81
m/f
f
r
m
f
m
ni
m
m
f
f
m
f
m
ni
r
r
m
m
f
m
m
r
m
duration
I'D years
9
4
5
12
6
18
11
5
2
4
12
14
3
8
9
7
9
15
13
7
4
19
21
H&Y
stage
4
2
3
3
4
4
3
2
3
1
3
4
1
2
2
3
4
3
4
2
1
3
4
= after Clozupine exposure
= before CIozapine exposure
duration
dopa
years
6
3
4
5
2
10
8
3
1
.2
8
10
1
5
6
4
2
11
9
3
1
12
16
dosage
levodopa
+ DDI
600
330
537
370
600
940
760
250
490
250
570
900
200
330
200
550
880
1000
1150
460
250
750
900
duration
Clozapine
months
7
10
8
6
7
6
6
10
6
3
9
13
7
16
9
8
7
18
21
14
6
17
19
dosage
Clozapine
mg
12.5
18.75
6.25
25.-
18.75
18.75
31.25
37.S0
12.50
12.50
18.75
12.50
25.-
31.25
6.25
12.50
18.75
6.25
12.50
18.75
12.50
31.25
18.75
UPDRS
items 18-31*
B
40
49
54
49
56
60
48
36
38
20
38
60
20
34
29
5!
65
52
75
33
12
40
76
A
35
39
47
51
49
57
39
29
34
19
37
63
13
28
31
44
61
52
73
30
13
33
72
Tremor score
items UPDRS*
B
17
21
23
14
6
19
26
24
11
9
13
22
22
19
6
8
6
4
9
13
8
21
15
A
11
9
18
14
2
13
22
16
8
6
13
B
13
12
6
4
3
1
3
13
8
14
8
Results
The clinical characteristics of the PD patients enroled in the trial are
summarized in table 1. Mean age was 63.5 ± 10.7 years, mean duration
of PD was 9.65 ± 5.2 years. Mean stage Hoehn and Yahr 2.83 ± 1.03
points. Mean duration of levodopatherapy 5.7 ± 4 years, the mean daily
dosage of levodopa was 576.8 mg with SD 285.8 mg. Mean Clozapine
daily dosage was 18.2 ± 8.6 mg and the mean duration of Clozapine
therapy was 10.3 months, with a SD of 5 months. Only one patient (nr
10) discontinued the scheduled minimum period of 6 months of study
because of leucopenia. All other patients wanted to proceed with
Clozapine therapy after the initial 6 months study period.
so-,
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Figure 1 Effect of clozapine on unified PDRS score, Tremor score and the difference
score (PDRS-Tremor). Mean score given above each bar. Standard deviation ( ± )
given in each bar. A star (*) indicates a significant difference (p<0.001) as showed by
a paired t-test.
Statistical analysis revealed that the tremor subscores before exposure
were significantly higher than those after exposure to Clozapine, the
means were 14.61 (SD = 6.83) and 10.43 (SD = 6.05) respectively
(t(22) = 5.90;p = 0.00). The UPDRS total scores before exposure to
Clozapine also proved to be higher than those after exposure
(t(22) = 4.82;p = 0.00). (see fig. 1)
The changes in mean UPDRS scores (before and after exposure
measurements) seem completely caused by the decrease of tremor
subscores. If the tremor subscores are subtracted from the UPDRS
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scores, the mean of the resulting UPDRS score is slightly higher after
exposure than before (mean difference = 0.43; SD = 2.39); this
difference is not statistically significant however (t(22)= - 1.34;p>0.20)
(see fig.l). A positive relationship was found between the change in the
tremor subscore ('delta tremor') and the dosage of Clozapine
administered (n = 23; Kendall's tau = 0.33; one-tailed p = 0.01)
In six patients hypersalivation was provoked by introduction of clozapine
medication. In three patients this hypersalivation was severe.
Naloxone was added in two patients, because of severe sedation.' In both
patients this naloxone medication was quite efficacious, it only was
necessary during weeks three to seven.
In most patients the effect of Clozapine (both the adverse events and the
antitremor efficacy) appeared within a few days. Six patients showed no
antitremor effect of Clozapine; the clinical characteristics of these six
patients were not different from the other 17 clozapine-responsive PD
patients. However, two of these six non-responsive patients also showed
definite sleep benefit from Clozapine, and two had a decrease of nausea
as is also seen in Clozapine-responsive patient.
Table 2. Side Effects - Clozapine treatment in 23 patients
total number of patients
Agranulocytosis 1 *
Sedation 8
Hypersalivation 6
Epilepsy 1
Decrease of nausea 5
Sleep benefit 11
Weight gain 3
Improvement of dyskinesias 1
* Lowest value of leucopenia 2.3
'* 2 of 8 patients requiring treatment with naloxone
*'* 3 of 6 patients were given biperiden
The adverse events are summarized in table 2. Neutropenia occurred in
one patient (nr 10); the blood count returned to normal values four
weeks after discontinuation of Clozapine treatment. Eleven patients
encountered a sleep benefit after Clozapine medication enabling in six
patients stopping their intermittent use of sleeping pills. Four of these
eleven patients however, also complained of daytime sedation, although
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this was only a problem in the first 3-4 weeks of Clozapine treatment.
One patient (nr 10) had a single generalized tonic-clonic seizure; in this
patient anti-epileptic drugs had been stopped six years before. The same
patient developed agranulocytosis.
One patient had a substantial benefit of Clozapine treatment in
improvement of levodopa induced dyskinesias. These dyskinesias were
bothersome for the patient and her partner, and had an orofacial
distribution (especially facial grimacing).
A special side effect encountered in three patients was weight-gain during
treatment with Clozapine. In one patient the weight-gain was 6 kilo-
grams.'"
In this study symptomatic orthostatic hypotension after Clozapine was not
seen.
Discussion
In previous reports"'' Clozapine treated PD patients had substantial
improvement of tremor. In this open label study 17 of 23 improved,
resulting in an overall beneficial response rate of 73%. We evaluated the
tremor improvement by the scores on the UPDRS, and found that the
statistically significant antitremor efficacy of Clozapine also explained the
improvement on the motor examination scores (items 18-31) of the
UPDRS. The effect of Clozapine on tremor is paradoxical, since in
previous reports tremor as an adverse event in psychiatric patients has
been described in 6 percent." The dosage of Clozapine in these
psychiatric patient, however, was much higher than the Clozapine dosage
used in this trial.
A low dosage of Clozapine (mean 18.2 mg/daily) did not increase the
other Parkinson disability scores of the UPDRS, as could be foreseen for
a drug labelled as an atypical antipsychotic. The same holds true for the
improvement - in one patient - of levodopa induced dyskinesias.
In this study one patient developed transient neutropenia which is the
major adverse event of Clozapine and which may be life threatening.'
The other - minor - adverse events of Clozapine could successfully be
diminished by administration of Naloxone for sedation. The exposure to
Clozapine - even in this low dosage - had a substantial weight-gaining
effect in some patients.'" Clozapine is related to the risk of seizures,'' and
this occurred in one patient with a previous history of epilepsy.
The exact pharmacological evidence to support the efficacy of Clozapine
as an atypical antipsychotic drug in psychosis and also in tremor is only
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partially understood. The selectivity of this new clinically active antipsy-
chotic compound on the Dl-D2/5HT2-receptors could account for the
unique spectrum of clinical effects of Clozapine. Clozapine has shown to
function more like a Dl than D2 antagonist, which could suggest a
distinction between typical and atypical antipsychotic drugs. Atypical
antipsychotics, like Clozapine and Fluperlapine, are potent 5HT2 and
5HT-1C antagonists, and thus may be expected to increase or modulate
DA cell activity in the midbrain. Compounds like Clozapine are capable
to alter the 5HT2/D2 balance."
Clozapine is the only compound to have an affinity for 5HT-1C sites that
is higher than that for the Dl and D2 sites.'" The D2 blocking activity of
Clozapine with a preferential binding to mesolimbic, mesocortical and
hippocampal D2 receptors, and no substantial binding to striatal
dopamine receptors is hold responsible for the only very weak extra-
pyramidal side effect profile of this compound.'* Clozapine does not
increase plasma prolactin (PRL) levels nor does it block the
apomorphine induced decrease in plasma PRL concentrations, these PRL
results may be consistent with an increased DA release of Clozapine."'
Antagonism of D2 and 5HT2 receptors, and enhancement of DA and
5 HT release may indeed be critical not only for the antipsychotic
properties of Clozapine, but also for the antitremor effect of Clozapine in
PD patients. The long duration of levodopatherapy in these patients may
obscure the precise mechanism of pharmacological activity of Clozapine
in PD patients with tremor. Clozapine also has shown to have strong
anti-noradrenergic, antihistaminergic and anticholinergic pharmacological
properties.^ Thus a defined theory fully accounting for the unusual
pharmacologie properties of Clozapine in the treatment of psychosis and
tremor still awaits further research.
On the basis of this study Clozapine seems indicated in PD patients with
severe disabling tremor, otherwise refractory to treatment. Clozapine can
be used safely if weekly white cell counts are - able to be - established.
Future research in this field must be directed to atypical neuroleptics,
with the same antitremor efficacy in PD patients, but devoid of the risk
of potentially fatal agranulocytosis.
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CHAPTER 11
Concluding Remarks
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This thesis deals with some aspects of Parkinson's disease (PD), with
special reference to recent momentous discoveries in the etiopathogenesis
of PD and to new developments in the pharmacotherapy of PD.
PD is a relentless progressive disorder and is a cause of miserable disabi-
lity. The discovery of selective striatal dopamine deficiency in the
parkinsonian brain in the early 1960s has improved insight in the
pathophysiology of PD substantially and has consequently led to a robust
decrease in the disability for the patient with PD. After the remarkable
finding that striatal dopamine content was reduced by 80% or more in
the brains of people with PD, because of destruction of the pigmented
nigral neurons, the disease was treated with levodopa to restore striatal
dopamine levels. [= >/« • ' « v - . : n ; - ; • ^
In the 1960s and 1970s high dose oral levodopa therapy was established
by Birkmayer, Hornykiewicz, Bernheimer and Cotzias. This is still the
most effective palliative pharmacotherapy ever found for PD. PD became
the first neurodegenerative disease to be treated effectively by
neurotransmitter replacement therapy. The finding of dopamine
deficiency in the basal ganglia of parkinsonian brains may also be seen as
a serendipity: in the early 1950s the introduction of antipsychotic drugs to
control schizophrenia led to the appearance of drug-induced
parkinsonism. The 1950s was the decade of the newly discovered
monoamine dopamine.
The next major advance was the design of synthetic directly acting
dopamine agonists, such as bromocriptine and pergolide, to stimulate a
variety of dopamine receptors. Apomorphine, widely used in clinical
psychiatry as a compound to provoke nausea and vomiting, was
rediscovered as a dopamine agonist. Much credit must be given in this
field of research to the Dutch pharmacologist Ernst.
After the discovery of dopamine and dopamine-agonists, agents were
designed to enhance and prolong the duration of action of dopamine in
the brain. Longer acting forms of levodopa have been introduced
('Madopar HBS', 'Sinemet CR' and 'Parlodel SRO')in the late 1980s,
since many patients developed unwanted side effects of dopamine
precursor therapy, response fluctuations (e.g. end of dose deterioration
and dyskinesias) and eventually waning efficacy. Inhibition of the major
catabolic enzyme of dopamine: monoamine-oxidase B - selegeline
hydrochloride (Deprenyl) - was another major event in the 1980s. The
large range of drugs available was believed to be palliative, mostly by
restoring striatal dopamine levels or activity; none was thought to protect
against the basic cause of PD, which was unknown. It seems reasonable
to remark that the discovery of MAO-B-inhibition was taking place in the
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research-field of psychiatry (Joseph Knoll), with the intention to design a
compound with anti-depressive properties. Moussa Youdim and Peter
Riederer actually must be regarded as the neuropharmacologists who
discovered MAO-B-inhibition as a potential drug in the treatment of P.D.
At the same time a disease - specific and age-specific increase in the
MAO-B-activity of the Parkinsonian brain had been established.
A pivotal role in further advance in the research of etiopathogenesis of
PD was the discovery in 1983 by Bill Langston of the identification of 1-
methyl-4-phenyl-l,2,3,6 tetrahydropyridine (MPTP) as a human
neurotoxin that could selectively destroy the substantia nigra, induce
neuropathological and neurochemical changes almost identical to those
of PD, and cause a clinical illness similar to Parkinson's disease itself.
MPTP is a pro-toxin, it must be converted to MPP + , in the glia by the
fore-mentioned MAO-B enzyme. MPP + , the active neurotoxin, is a
substrate for the active dopamine neuronal uptake. MPP+ is thus
concentrated into dopaminergic neurons where it binds to neuromelanin -
a byproduct of dopamine synthesis found in nigral cells. The
intraneuronally accumulated MPP+ is taken up and concentrated in
mitochondria, where it poisons NADH-linked components of complex I
of mitochondrial energy metabolism. MPP+ also may induce the
formation of free radical species, imposing oxidative stress with
consequent lipid membrane peroxidation. MPP+ may also poison
mitochondrial complex I activity as a result of free radical damage. Thus
a number of biochemical abnormalities, which appear to be playing a role
in the nigral cell death in PD, have been disclosed in recent years:
1. Mitochondrial complex I deficiency in the substantia nigra, in the
nigral melanin-containing and tyrosine-hydroxylase positive dopamine
neurons.
Similar but less severe changes have also been found in the aging
substantia nigra. Mizuno found an increase in deleted mtDNA in PD
patients.
2. Iron accumulation. Iron content in substantia nigra is significantly
increased in PD. Iron will react with hydrogen peroxide to form
hydroxyl radicals in the presence of Fe"* , and thus may induce
oxidative damage to nigral cells.
Moreover iron itself is cytotoxic: it directly decreases the number of
tyrosine-hydroxylase neurons.
3. Oxygen free radicals. An increase in lipid peroxidation has been
reported in PD suggesting reactive oxygen production. Free radical
theory and iron theory are closely related.
4. Neurotoxin. Some of the derivatives of tetrahydroisoquinolines and B-
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carbolines are MPTP-analogues, and are toxic to mitochondrial
respiratory complexes.
5. Cytochrome P 450. Recent reports have established poor metabolizers
of debrisoquine hydroxilation or acetaminophen - sulphation, with an
increased risk for acquiring Parkinson's disease. In such cases even a
weak toxin may induce nigral damage.The reverse may also be
relevant: a genetically arranged metabolic make up of increased N-
methylation of tetrahydroisoquinolines putatively may be associated
with increased risk for acquiring Parkinson's disease.
All these mechanisms in the pathogenesis of nigral cell death in PD will
eventually lead to alterations in the therapeutic management of
Parkinson's disease, early diagnosis of PD, detection of the preclinical
phase of PD, and establishment of the most effective use of
neuroprotective agents. Neuronal rescue is the most recent finding in the
'post MPTP' period providing evidence that non-MAO-B-inhibition or
low dosage selegiline may activate a 'neurotrophic-like' mechanism. This
'neuronal rescue' is very important in the research on
neurotransplantation or brain grafting of fetal substantia nigra into the
striatum, especially the survival of such grafts and the potency for
regeneration. But the 'neuronal rescue', of course, might also be very
important for alleviation of the actual degeneration of nerve cells in the
substantia nigra of the parkinsonian brain.
The agents related to neuronal rescue and neuroprotection have immense
implications for substantially influencing the underlying pathology of PD,
and possibly also other primary degenerative neurological disorders, like
Alzheimer's disease and Motor Neuron Disease.
Confined to Parkinson's disease the major implications are:
1. All newly diagnosed cases of PD should be started on a drug that
has shown neuroprotective or neuronal rescue properties.
2. Methods of diagnosing the illness at its earliest stage (or even
before motor and non-motor symptoms are present) should be
developed.
3. Neuroprotection and Neuronal Rescue can postpone or delay
palliative pharmacotherapy with dopamine-precursors and
dopamine-agonists. Pharmacotherapy with these agents has many
adverse events and may have only a temporary benefit.
4. Treatment of Parkinson's disease by implantation procedures will
be critically dependent on these neuroprotective and neuronal
rescue procedures.
/2P
As to the present therapeutic management of symptoms of PD the
observations made in this study justify some global conclusions.
* Selegiline should be considered among the available therapeutic
options for the initial treatment of PD.
* Sustained release levodopa and dopamine-agonists compounds are
beneficial in the palliative treatment of PD, and in the short-term
treatment of response fluctuations.
* Apomorphine has shown to be very effective in parkinsonian patients
with severe response fluctuations.
* Pharmacological modelling of D1/D2 agonism and antagonism in
combination with activity on a variety of 5HT receptors may be
beneficial in the treatment of neurobehaviourial, cognitive and dopa-
unresponsive symptoms in patients with PD, with or without long-
standing levodopa and/or dopamine-agonists therapy
Parkinson's disease is much more than a dopamine deficiency in the basal
ganglia, and also is much more than a pure motor disorder. We all await
the second Wartenberg-lecture of David Marsden "The mysterious non-
motor function of the basaJ ganglia".
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CHAPTER 12
SUMMARY and SAMENVATTING
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Summary
This thesis deals with pharmacotherapy in Parkinson's disease. General
aspects of the pathogenesis and medical treatment of Parkinson's disease
are discussed, and some particular aspects of the treatment and the
complications of treatment are dealt with in more detail.
Chapter 1 is a general introduction and describes the clinicopathologic
features of Parkinson's disease, the problems with diagnostic criteria of
idiopathic Parkinson's disease and Parkinsonism. The new classification
criteria of the United Kingdom Parkinson's disease Society Brain Bank
facilitate a more reliable diagnosis, mainly based on inclusion and exclusi-
on criteria. The accuracy of the clinical diagnosis of idiopathic Parkin-
son's disease is debated, establishing that about 25 percent of patients
with a clinical diagnosis of Parkinson's disease actually have other causes
of parkinsonism. Clinical heterogeneity is common even in patients
unquestionably diagnosed as having Parkinson's disease. Changing
concepts of Parkinson's disease with respect to both the clinical and the
pathological spectra also hamper a definite answer to the genetic
etiologic factors in Parkinson's disease.
Chapter 2 gives a review on the rationale of pharmacotherapy in
Parkinson's disease. Symptomatic therapy with dopamineprecursors is
discussed, which is based on the deficiency of nigrostriatal dopamine and
tries to enhance dopaminergic transmission in the basal ganglia.
Levodopatherapy is the backbone of pharmacotherapy in Parkinson's
disease. Slow-release levodopa preparations and dopamine agonists are
mainly used to alleviate or prevent the levodopa and disease related
response-losing and response-fluctuations. Special attention has been
given in this chapter to recent insight in the possibility of neuroprotection
and neuronal rescue, referring to a growing interest in slowing
progression of PD by protecting surviving neurons. Bill Langston's finding
that MPTP can induce Parkinsonism and that deprenyl prevents MPTP-
induced Parkinsonism, has played a pivotal role in the stimulated interest
in anti-oxidative therapy. Recently the MAO-B-inhibiting property of
deprenyl has been extended to MAO-B independent actions of deprenyl,
based on the hypothesis that deprenyl increases trophic support to
damaged neurons by adjacent reactive astrocytes.
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Chapter 3 describes the topic of neuroprotection by the MAO-B-inhibitor
selegiline in some detail. Although the primary cause of Parkinson's
disease remains unknown, four theories assign an essential role in the
putative mechanisms leading to cell death in the zona compacta of
substantia nigra. These theories are discussed:
1. Iron (Fe~*) is cytotoxic and leads eventually to decrease of striatal
dopamine.
2. Environmental neurotoxins (like MPTP) imitate idiopathic Parkinson's
disease extremely closely; the ultimate mechanism of cell killing is
presumably mitochondrial complex I poisoning.
3. Endogenous MAO-B mediated (auto-)oxidation of dopamine leads to
the production of toxic oxygen free radicals with potential for nigral
degeneration.
4. Inherited variations in handling of xenobiotics and endogenous toxins
could lead to increased susceptibility to Parkinson's disease.
The results of the DAT ATOP trial are discussed. These deprenyl studies
of patients in early stages of Parkinson's disease support a
recommendation for treating these patients with deprenyl 10 mg/day. It
has proven unlikely that these studies will provide conclusive data
regarding the mechanism of Deprenyl's benefit in Parkinson's disease.
Chapter 4 describes the results of a multicenter study on the potency of
the oral slow-release levodopa preparation Madopar HBS to alleviate
response fluctuations. Patients with clear-cut 'wearing-off type of
response fluctuations seem particular good candidates for the treatment
of these newly developed levodopa preparations. Random oscillations
and freezing-episodes were found to be resistant to slow-release levodopa
oral administration regimes. Especially in severely disabled patients the
therapeutic response to the first morning dose of Madopar HBS
appeared too slowly, and therefore a combination with standard Madopar
still seems necessary.
Chapter 5 describes a study in co-operation with the late Jan Meerwaldt,
of the use of Madopar HBS in Parkinsonian patients with nocturnal and
early-morning disabilities. Although James Parkinson in his Essay on the
Shaking Palsy observed that sleep came as a merciful release to sufferers
of the malady, for many individuals with Parkinson's disease the night
brings with anguish, pain and a crippling despair. In an attempt to
combat some of the areas of nocturnal difficulty, patients in this study
took Madopar HBS before retiring. This anti-noctum levodopa regimen
did lead to a considerable diminution in nocturnal akinesia and in the
frequency of waking-up. The results provoked by Madopar HBS on these
nocturnal akinetic wearing-off phenomena are in agreement with the
pharmacokinetic profile of this preparation. ,. ..,.,,._... , ... .. ,..
Chapter 6 reports the results of a national multicenter study ( by the
Dutch Sinemet Study Group ) on the experiences of the clinical efficacy
of Sinemet CR versus standard Sinemet in patients with fluctuating
Parkinson's disease. The fourth generation of controlled-release
carbidopa/levodopa, termed Sinemet CR, is formulated as a slowly
erodible matrix containing carbidopa and levodopa. In this double-blind
randomized study Sinemet CR showed to be superior in efficacy:
reduction in fluctuations in motor performance. The results in this study
on the short-term beneficial effect of slow-release levodopa preparations
are a consequence of more constant levodopa plasma levels, and thus
confirm the hypothesis that response fluctuations may in part be
attributed to the pharmacokinetic properties of oral levodopa, a quick-
release formulation with a short plasma half-life.
Chapter 7 describes the results of a national double blind randomized
study comparing the efficacy and tolerability of standard bromocriptine
versus sustained-release bromocriptine. The introduction of therapy with
standard bromocriptine is frequently complicated by peripheral adverse
events, mainly concerning orthostasis and nausea. These unwanted effects
prevent reaching an effective dosage of bromocriptine. Parlodel SRO was
superior compared to standard Parlodel in tolerance, and thus it is seems
possible for more Parkinson patients to be treated with this dopamine
agonist in effective dosages.
Chapter 8 describes some results of the research group of the
Neuropharmacology department in Medisch Spectrum Twente in
Enschede with that oldest dopamine-agonist: Apomorphine. The
rediscovery of Apomorphine, which is active at both D-l and D-2
receptors, has essentially been achieved by the Middlesex Hospital
Research Group in London (Andrew Lees, Gerald Stern and Merton
Sandier). Enschede was able to take the position of a 'satellite' research
unit. Apomorphine is used in the search for D2 receptor status in the
diagnostic phase of Parkinson's disease. Apomorphine is extremely
efficacious in the treatment of 'off periods, by subcutaneous injections,
and in the continuous treatment by subcutaneous infusion using portable
pumps. As an alternative to subcutaneous injections, intranasal
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administration of Apomorphine is also quite an efficacious and reliable
method to overcome 'off status. Also reported is an original study of the
pharmacokinetics of Apomorphine levels in cerebrospinal fluid and
plasma. This research indicated that Apomorphine levels in the
cerebrospinal fluid reflect the pharmacologie motor effects of
Apomorphine administration in Parkinson patients more accurately than
the conventional estimation of Apomorphine plasma levels.
Chapter 9 reports an unsuspected adverse event of anti-depressant
treatment in Parkinson's disease. Depression is only recently a major
focus of study in PD, although there is little controversy regarding the
frequency of depression in Parkinson's disease.
Nearly half of the patients with Parkinson's disease are depressed, the
most frequent forms of which are major depression and dysthymic
disorders. Especially depression with psychomotor retardation seems to
be more or less specific for a neurologic disorder with dopamine
deficiency in the basal ganglia. The report describes the increase of
Parkinson disability after fluoxetine medication, underlining indirect
dopamine-antagonistic properties of this serotonin re-uptake inhibitor
and the intimate link between serotonin and dopamine in the
pathogenesis of signs and symptoms of Parkinson's disease.
Chapter 10 also deals with the dopamine and serotonin interplay in the
symptomatology of Parkinson's disease. Atypical neuroleptics, like
Clozapine, combine pharmacological actions on dopamine and serotonin
receptors, and confirm the serotonin and dopamine interactions in the
nigrostriatal and mesolimbic pathway. Although the relevance of
dopaminergic deficiency for the pathophysiology of tremor in PD is at
least questionable, the ratio of serotonin and dopamine affinity may be
critical for the role of Clozapine in alleviating tremor in Parkinson's
disease. The potentially fatal agranulocytosis provoked by Clozapine in a
frequency of 1% is a caution, of course, against gratuitous use of this
compound in neuro-psychiatry.
Chapter 11 - concluding remarks - gives a historical review of momentous
discoveries in the neuropharmacology of PD, and summarizes some
implications for pharmacotherapy in PD.
Chapter 12 summarizes our findings, and reviews the conclusions of the
separate chapters.
All chapters have been published or are accepted for publication. These
separate papers consequently are more or less repetitious, which does
give resemblance to scientific papers in general.
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Samenvatting
In dit proefschrift worden enkele aspecten van farmacotherapie bij de
Ziekte van Parkinson besproken. Een overzicht wordt gegeven van de
conventionele en de meer récente inzichten in de pathogenese en de
medicamenteuze thérapie bij de Ziekte van Parkinson. Ook enkele
bijzondere behandelingsmodaliteiten worden beknopt of zelfs anekdotisch
beschreven.
Hoofdstuk 1 is bedoeld als inleiding in de kliniek, de pathofysiologie en
de differentiaal diagnostiek van de Ziekte van Parkinson. Inclusie- en
exclusie-criteria voor het stellen van de diagnose 'Ziekte van Parkinson'
worden beschreven, o.a. aan de hand van de meer récente classificatie-
criteria van de Engelse 'Parkinson's disease Society Brain Bank'. Er zijn
veel aanwijzingen - vooral gebaseerd op studies tot stand gekomen door
een hechte samenwerking van klinisch neuroloog en neuropatholoog - dat
de nosologische entiteit 'De Ziekte van Parkinson' niet zo duidelijk
omschreven kan worden. Het is derhalve wellicht zinvol termen als
Idiopathisch Parkinsonisme, Syndroom van Parkinson of Lewy Body
Disease te gebruiken. Klinisch neurologische en neuropathologische
diagnostische criteria kunnen bovendien weinig gebruikt en gewaardeerd
worden indien - zoals toenemend wordt beschreven en herkend - er een
overlapping is van verschillende neurologische degeneratieve
ziektebeelden als Ziekte van Parkinson, Ziekte van Alzheimer en
Amyotrofische Lateraalsclerose. Voor het parkinsonisme is dan wellicht
typisch de hyperactiviteit van dopaminerge neuronen (o.a. in de
substantia nigra) die tot eerdere celsterfte aanleiding geeft. Een typisch
'wear and tear' gebeurtenis dus.
Hoofdstuk 2 geeft een overzicht in de medicamenteuze thérapie bij de
Ziekte van Parkinson. De symptomatische palli itieve behandeling met
levodopa wordt uitvoerig besproken: tengevolge van degeneratieve
afwijkingen in de substantia nigra ontstaat een min of meer selectief
defect van het enzym tyrosine hydroxylase, het exogeen toegediende
levodopa kan het al langdurig aanwezige dopamine tekort in de basale
ganglien 'overwinnen' en de postsynaptische dopamine transmissie 'weer
aan de gang krijgen' met aile klinisch-functionele gevolgen van dien.
Levodopamedicatie bij de Ziekte van Parkinson is nog steeds de meest
succesvolle thérapie - ook op de lange termijn. Een afgeleide van de
levodopatherapie is de levodopa met vertraagde afgifte in het
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maagdarmkanaal. Tengevolge van de farmacokinetische eigenschappen en
beperkingen van levodopa en dopamine kunnen Madopar HBS en
Sinemet CR de 'eb en vloed' mechanismen van conventioneel oraal
levodopa verminderen en een meer continue stroom van levodopa en
dopamine aan de basale ganglien toeleveren. Dopamine-agonisten -
vooral indien voorzien van een lange halfwaardetijd - kunnen een zelfde
effect te weeg brengen.
Behalve deze symptomatische medicamenteuze behandeling van de
Ziekte van Parkinson, zijn er recent ook argumenten om
neuroprotectieve medicamenten voor te schrijven. Neuroprotectie is
gebaseerd op de hypothèse dat de verschillende pathogenetische
mechanismen die een rol spelen bij de Ziekte van Parkinson (oxydatieve
stress, defecte mitochondriale complex I activiteit, en excessieve belasting
met 'excitatory amino acids') een continue beschadigende factor vormen
voor de dopaminerge neuronen, en dat met medicamenten als MAO-B-
remmers de resterende (door compensatie overactieve) dopaminerge
neuronen verdere beschadiging kan worden verminderd of zelfs
voorkomen. Cruciaal in dit opzicht was de ontdekking dat MPTP, een
aan héroïne verwante stof, parkinsonisme kan veroorzaken en dat MAO-
B-remmers deze selectieve toxiciteit van de dopaminerge neuronen in de
substantia nigra door MPTP kan voorkomen. Wellicht zijn het de
neurotrofische eigenschappen van deze preparaten die een zodanige
beschermende werking tot stand brengen (de zogenaamde 'neuronal
rescue'). Het 'Occam's razor' geldt dan dus ook voor de dosering van een
preparaat dan ten onrechte een 'MAO-B-remmer' wordt genoemd.
Hoofdstuk 3 behandelt in meer uitgebreide zin het onderwerp van
neuroprotectie zoals dat mogelijk wordt gerealiseerd door de MAO-B-
remmer Selegiline. Met neuroprotectie wordt dan uitdrukking gegeven
aan een bescherming van de zona compacta cellen in de substantia nigra
tegen vier schadelijke factoren.
1. Uzer (Fe^J is schadelijk voor de eel en er zijn argumenten voor een
overbelasting aan ijzer voor de genoemde dopaminerge cellen.
2. Neurotoxines, zoals MPTP, kunnen selectief de dopaminerge neuronen
beschadigen, en als zodanig parkinsonverschijnselen - zowel klinisch als
neuropathologisch - doen ontstaan.
Metabolieten van het MPTP zijn zeer toxisch voor het complex 1
gedeelte van de mitochondrion in de neuronen en kunnen op deze
manier celsterfte bewerkstelligen.
3. Auto-oxydatie van het endogène dopamine door het overvloedig
aanwezige MAO-B-enzym kan toxische zuurstofradicalen genereren die
direct (lipidenperoxydatie) of indirect (complex I) de celdegeneratie
veroorzaken.
4. Erfelijke factoren die de snelheid en de effectiviteit van detoxificatie
van endogène of exogène toxines bepalen.
In dit hoofdstuk worden de resultaten van de DATATOP studie bespro-
ken. Deprenyl (Selegiline) thérapie bij de-novo Parkinson patiënten kan
de thérapie met levodopa uitstellen. Hoewel de interpretatie van de
resultaten van deze DATATOP studie niet eenduidig is en kan worden,
heeft een en ander er wel toe geleid dat Deprenyl wordt voorgeschreven
als eerste keuze preparaat bij de medicamenteuze behandeling van de
Ziekte van Parkinson.
Hoofdstuk 4 behandelt de resultaten van een Nederlandse multicenter
studie met het preparaat Madopar HBS, een levodopa met vertraagde
afgifte, bij de behandeling van Parkinson patiënten met responsfluctua-
ties. Patiënten met voorspelbare schommelingen in motoor prestatieni-
veau bleken gunstig te reageren op Madopar HBS. Dit bleek niet het
geval met andersoortige responsfluctuaties. Een nadeel van het Madopar
HBS, namelijk de verlaging van Cmax en de verlenging van de Tmax,
veroorzaakt veelal echter verminderde werkzaamheid vooral 's morgens.
Monotherapie met Madopar HBS blijkt dan ook in het geval van al
aanwezige responsfluctuaties niet goed mogelijk.
Hoofdstuk 5 is een artikel over de effectiviteit van Madopar HBS bij de
nachtelijke problemen zoals door veel patiënten met de Ziekte van
Parkinson worden ervaren. Er zijn wel aanwijzingen dat er bij de Ziekte
van Parkinson slaapstoornissen in engere zin zijn, maar zeker worden
vele Parkinson patiënten in hun slaap gestoord door effecten van levodo-
pa, zoals 'wearing-off fenomeen in de nacht en onrustige slaap ('vivid
dreams'). Madopar HBS had een gunstig effect bij veel patiënten in de
studie op de nachtelijke problemen. Deze studie was een gevolg van de
zeer gewaardeerde samenwerking met Dr. Jan Meerwaldt.
Hoofdstuk 6 is het artikel van de GSSH (Gemengde Studie Sinemet
Holland). Het bevat de resultaten van een studie met Sinemet CR en
standaard Sinemet bij Parkinson patiënten met responsfluctuaties.
Sinemet CR geeft door langzame erosie van zijn matrix in niet-zuurmilieu
een vertraagde afgifte van carbidopa en levodopa. In vergelijking met
standaard Sinemet was er een significante vermindering van het aantal
fluctuaties in motoor prestatieniveau. De betrouwbaarheid van de
Parkinson patient en zijn partner bij het registreren van respons-
fluctuaties werd aog eens bevestigd, evenals de moeilijkheid om een
dubbelblinde onderzoeking te verrichten met twee zo verschillende
levodopapreparaten.
Hoofdstuk 7 is een weergave van de Nederlandse multicentrische studie
met standaard Parlodel en Parlodel SRO. Het betreft een vergelijkende
dubbelblinde studi. naar de effectiviteit en de tolerantie van deze twee
dopamine-agonisten. Met name werd gekeken of bij gelijkblijvende
effectiviteit een verbeterde tolerantie kan worden gerealiseerd met
behulp van Parlodel SRO. Dit bleek inderdaad het geval. Vooral misse-
lijkheid en orthostase kwamen minder voor in de met Parlodel SRO
behandelde groep van patiënten. Daardoor kan een eenvoudige en betere
introductie van deze dopamine-agonist worden bereikt bij een groter
aantal Parkinson patiënten.
Hoofdstuk 8 is een weergave van enkele studies met de dopamine-agonist
apomorphine, zoals deze konden plaatsvinden in de werkgroep neurofar-
macologie van het ziekenhuis Medisch Spectrum Twente in Enschede.
Apomorphine is onstabiel, moeilijk oplosbaar en lokaal toxisch, maar bij
gebruik parenteraal onstaat een bijna wonderlijke en snelle antiparkin-
sonwerking; een verbetering die in veel opzichten gelijkt - ook in snelheid
- op de verbetering van myasthénie symptomen na Tensilon injectie.
Hoofdstuk 9 beschrijft een onverwachte bijwerking van antidepressieve
medicamenteuze behandeling bij enkele Parkinson patiënten. Na gebruik
van Fluoxetine medicatie ontstond een toename van Parkinson-
verschijnselen, mogelijk veroorzaakt door indirecte dopamine-
antagonistische eigenschappen van deze serotonine re-uptake remmer.
Deze casuïstische mededeling bevestigt de sterke koppeling tussen de
neurotransmitters Serotonine en Dopamine bij de pathogenese van
klachten en verschijnselen van de Ziekte van Parkinson.
Hoofdstuk 10 beschrijft de gunstige effecten van een lage dosering van
het atypische neurolepticum Clozapine bij de tremor van Parkinson
patiënten. Clozapine heeft een D1/D2 ratio die hoger is dan bij de
conventionele neuroleptica en in combinatie met aangetoonde
serotonerge eigenschappen van dit preparaat is wellicht een verklaring te
vinden voor het zo bijzondere antitremor effect. Clozapine kan echter
een fatale agranulocytose veroorzaken, zodat het voorschrijven van dit
preparaat aan strikte regels, voor wat betreft laboratorium-controles
onder verantwoordelijkheid van de voorschrijvende arts, is gebonden.
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Hoofdstuk 11 geeft een historisch overzicht van de neurofarmacologische
ontwikkelingen bij de Ziekte van Parkinson en geeft de consequenties
voor de farmacotherapie bij deze ziekte in grote lijnen aan.
De hoofdstukken 12 en 13 geven een samenvatting van de verschillende
pathogenetische en neurofarmacologische ontwikkelingen.
Ieder hoofdstuk is een weergave van een publicatie. Het geheel van
artikelen dat aldus door bundeling is ontstaan, probeert meer inzicht te
verschaffen in het enigma dat de Ziekte van Parkinson is.
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